US 5,223,485 AGrant
Anaphylatoxin-Receptor Ligands
Issue Date:1993-06-29
•6 Claims
Abstract
Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q-T are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.
Metadata
Assignee
- Abbott Laboratories
Inventors
- Megumi Kawai
- Yat S. Or
- Paul E. Wiedeman
- Jay R. Luly
- Mikel P. Moyer
Application Information
Application Number:US 6910394
Filing Date:1991-06-19
Priority Date:1989-01-31
Art Unit:181
Classifications
IPC:
A61K 3702A61K 3700C07K 500C07K 700
Field of Search:
51453016;17329;328
Patent Drawings
This patent does not have any drawings.
Description
TECHNICAL FIELD
This invention relates to organic compounds that modulate anaphylatoxin activity. It also relates to methods and compositions for modulating anaphylatoxin activity in human and animal hosts in need of such treatment.
BACKGROUND OF THE INVENTION
A wide variety of conditions including infection by bacteria, viruses or fungi, infiltration by cancer cells, allergic or autoimmune disorders and physically- or chemically-induced trauma causes an inflammatory response in humans. In all of these diseases and conditions in man and in most mammals, activation of the complement system (a set of proteins, regulatory factors and proteolytic enzymes) via either the classical or the alternative pathway results in the generation of biologically active peptides which serve to amplify and exacerbate the resulting inflammation. The most active peptide, anaphylatoxin C5a, a 74-amino acid polypeptide, is generated by cleavage of the alpha-chain of native C5 at a specific site by convertases (proteolytic enzymes) of the blood complement system as well as by enzymes of the coagulation system. C5a exists in vivo in two biologically active forms. Once it is liberated from C5, the carboxyl terminal arginine of C5a is rapidly removed by carboxypeptidase-N, leaving the des-Arg derivative. Although C5a des-Arg is less active than C5a, both are potent inflammatory mediators at concentrations likely to be generated in vivo (Fernandez, H. N.; Henson, P. M.; Otani, A.; Hugli, T. E. J. Immunol. 1978, 120, 109.). Together, these peptides along with C3a, C4a, and their des-Arg degradation products, collectively described herein as anaphylatoxin, are capable of triggering diverse inflammatory reactions.
Among the various cell types, the neutrophil response to C5a is the best defined. Cell surface receptors specific for C5a have been demonstrated on the neutrophil (Chenoweth, D. E.; Hugli, T. E. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 3943-3947. Huey, R.; Hugli, T. E. J. Immunol. 1985, 135, 2063-2068. Rollins, T. E.; Springer, M. S. J. Biol. Chem. 1985, 260, 7157-7160.), and the ligand-receptor interaction promotes human polymorpho-nuclear leukocyte (PMN) migration in a directed fashion (chemotaxis), adherence, oxidative burst, and granular enzyme release from these cells (Hugli, T. E. Springer Semin. Immunopathol. 1984, 7, 193-219.). The interaction of C5a with PMN and other target cells and tissues results in increased histamine release, vascular permeability, smooth muscle contraction, and an influx into tissues of inflammatory cells, including neutrophils, eosinophils, and basophils (Hugli, T. E. Springer Semin. Immunopathol. 1984, 7, 193-219.). C5a may also be important in mediating inflammatory effects of phagocytic mononuclear cells that accumulate at sites of chronic inflammation (Allison, A. C.; Ferluga, J.; Prydz, H.; Scherlemmer, H. U. Agents and Actions 1978, 8, 27.). C5a and C5a des-Arg can induce chemotaxis in monocytes (Ward, P. A. J. Exp. Med. 1968, 128, 1201. Snyderman, R.; Shin, H. S.; Dannenberg, A. C. J. Immunol. 1972, 109, 896.) and cause them to release lysosomal enzymes (McCarthy, K.; Henson, P. S. J. Immunol. 1979, 123, 2511.) in a manner analogous to the neutrophil responses elicited by these agents Recent studies suggest that C5a may have an immunoregulatory role by enhancing antibody particularly at sites of inflammation (Morgan, E. L.; Weigle, W. O.; Hugli, T. E. J. Exp. Med. 1982, 155, 1412. Weigle, W. O.; Morgan, E. L.; Goodman, M. G.; Chenoweth, D. E.; Hugli, T. E. Federation Proc. 1982, 41, 3099. Morgan, E. L.; Weigle, W. O.; Hugli, T. E. Federation Proc. 1984, 43, 2543.).
C5a and C5a des-Arg play important roles in host defenses against bacterial infections and possibly in the mediation of some pathologic lesions such as the leukocyte infiltration seen in the lungs during acute respiratory distress syndrome. This mechanism seems to play a role in different pathological situations like pulmonary distress during hemodialysis, leukophoresis, cardiopulmonary bypass, and in acute myocardial infarction Complement activation has been postulated to play an important pathological role in rheumatoid arthritis, serum sickness, systemic lupus erythematosus, ulcerative colitis, and forms of hepatic cirrhosis, chronic hepatitis, and glomerulonephritis, in certain shock states, during hemodialysis, and cardiopulmonary bypass, acute pancreatitis, myocardial infarction (which may be worsened by C5a-induced leukoembolization following the interaction of complement with atheromatous plaques), asthma, bronchoconstriction, some auto-allergic diseases, transplant rejection, and post-viral encephalopathies.
By serving as antagonists by binding to and blocking the anaphylatoxin receptor, certain compounds of the present invention can reduce or prevent anaphylatoxin-mediated inflammation. Other compounds of the present invention are agonists that mimic anaphylatoxin activity, and assist the body in building its defense mechanism against invasion by infectious agents and malignancy. Additionally, these compounds may influence the immunoregulatory effects of anaphylatoxin. The possible involvement of anaphylatoxin in a wide range of diseases, as indicated by these examples, suggests that anaphylatoxin receptor ligands could have clinical applications for the treatment and prevention of the above-mentioned pathological conditions.
SUMMARY OF THE INVENTION
In accordance with the principal embodiment of the present invention, there are provided anaphylotoxin activity modifying compounds of the formula A-B-D-E-G-J-L-M-Q-T and the pharmaceutically acceptable salts, esters, or amides thereof.
In the generic formula given above, the groups A through T have the following values:
A is R.sub.1 -R.sub.2 -R.sub.3 ;
B is selected trom R.sub.4 -R.sub.5 -R.sub.6, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
D is selected from R.sub.7 -R.sub.8 -R.sub.9, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
E is selected from R.sub.10 -R.sub.11 -R.sub.12, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
G is selected from R.sub.13 -R.sub.14 -R.sub.15, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
J is selected from R.sub.16 -R.sub.17 -R.sub.18, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
L is selected from R.sub.19 -R.sub.20 -R.sub.21, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
M is selected from R.sub.22 -R.sub.23 -R.sub.24, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
Q is selected from R.sub.25 -R.sub.26 -R.sub.27, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ;
T is R.sub.28 -R.sub.29 -R.sub.30 ;
B and D, taken together, optionally represent a group selected from R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ;
D and E, taken together, optionally represent a group selected from R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ;
E and G, taken together, optionally represent a group selected from R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ;
G and J, taken together, optionally represent a group selected from R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ;
J and L, taken together, optionally represent a group selected from R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ;
L and M, taken together, optionally represent a group selected from R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ; and
M and Q, taken together, optionally represent a group selected from R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43, and
one or more of the groups R.sub.5 -R.sub.6 -R.sub.7 ; R.sub.8 -R.sub.9 -R.sub.10 ; R.sub.11 -R.sub.12 -R.sub.13 ; R.sub.14 -R.sub.15 -R.sub.16 ; R.sub.17 -R.sub.18 -R.sub.19 ; R.sub.20 -R.sub.21 -R.sub.22 ; R.sub.23 -R.sub.24 -R.sub.25 ; or R.sub.26 -R.sub.27 -R.sub.28, independently optionally represent R.sub.36.
The group R.sub.1 is selected from the group consisting of amino, (lower alkyl)amino, dialkylamino, (arylalkyl)amino, hydroxy, alkoxy, aryloxy, arylalkoxy, acetamido, thioalkoxy, halogen, aryl, lower alkyl, arylalkyl, (heterocyclic)alkyl, heterocyclic, arylamino, and hydrogen.
R.sub.2 is selected from the group consisting of >CR.sub.99 R.sub.100, >C.dbd.CR.sub.95 R.sub.96, existing in either the Z- or E-configuration, oxygen, amino, and alkylamino, with the proviso that when R.sub.2 is oxygen, amino or alkylamino, R.sub.1 is aryl, lower alkyl, arylalkyl or (heterocyclic)alkyl.
R.sub.3 is selected from the group consisting of >C.dbd.O, >CH.sub.2, >C.dbd.S, and >SO.sub.2, with the proviso that when R.sub.3 is >CH.sub.2 or >SO.sub.2 then R.sub.2 cannot be oxygen, amino or alkylamino.
R.sub.4 is selected from the group consisting of >CH.sub.2, >O, >S, and >NR.sub.101 where R.sub.101 is hydrogen, lower alkyl, arylalkyl, alkenyl, hydroxy or alkoxy, with the proviso that when R.sub.4 is >O or >S then R.sub.1, R.sub.2 and R.sub.3 taken together represent a group selected from lower alkyl, arylalkyl, aryl or hydrogen.
R.sub.5 is selected from the group consisting of >CR.sub.201 R.sub.202, >NR.sub.203, >C.dbd.CR.sub.205 R.sub.206, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR1##
R.sub.6, R.sub.9, R.sub.12, R.sub.15, R.sub.18, R.sub.21, and R.sub.24 are independently selected from the group consisting of >C.dbd.O, >CH.sub.2, --CH.sub.2 C(O)--, --NHC(O)--, >C.dbd.S, >SO.sub.2, and >P(O)X where X is selected from hydroxy, alkoxy, amino, alkylamino and dialkylamino.
R.sub.7, R.sub.10, R.sub.13, R.sub.16, R.sub.19, R.sub.22, R.sub.25 are independently selected from >CH.sub.2 and >NR.sub.50 where R.sub.50 is selected from the group consisting of hydrogen, lower alkyl, arylalkyl, aryl, hydroxy and alkoxy.
R.sub.8 is selected from the group consisting of >CR.sub.210 R.sub.211, >NR.sub.213, >C.dbd.CR.sub.215 R.sub.216, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR2##
R.sub.11 is selected from the group consisting of >CR.sub.220 R.sub.221, >NR.sub.223, >C.dbd.CR.sub.225 R.sub.226, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR3##
R.sub.14 is selected from the group consisting of >CR.sub.230 R.sub.231, >NR.sub.233, >C.dbd.CR.sub.235 R.sub.236, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR4##
R.sub.17 is selected from the group consisting of >CR.sub.301 R.sub.302, >NR.sub.303, >C.dbd.CR.sub.305 R.sub.306, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR5##
R.sub.20 is selected from the group consisting of >CR.sub.310 R.sub.311, >NR.sub.313, >C.dbd.CR.sub.315 R.sub.316, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR6##
R.sub.23 is selected from the group consisting of >CR.sub.320 R.sub.321, >NR.sub.323, >C.dbd.CR.sub.325 R.sub.326, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR7##
R.sub.26 is selected from the group consisting of >CR.sub.330 R.sub.331, >C.dbd.CR.sub.335 R.sub.336, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR8##
R.sub.27 is selected from the group consisting of >C.dbd.O, >CH.sub.2, --CH.sub.2 C(O)--, >C.dbd.S, >SO.sub.2, and >P(O)X where X is selected from hydroxy, alkoxy, amino, alkylamino and dialkylamino.
R.sub.28 is selected from the group consisting of >O, >S, >CH.sub.2, and >NR.sub.109 where R.sub.109 is selected from hydrogen, lower alkyl, (heterocyclic)alkyl, and arylalkyl, with the proviso that when R.sub.27 is >SO.sub.2 or >P(O)X, then R.sub.28 is >O or >NR.sub.109.
R.sub.29 is selected from the group consisting of hydrogen, lower alkyl, arylalkyl, and >NR.sub.110 where R.sub.110 is selected from hydrogen, lower alkyl, aryl, and arylalkyl, with the provisos that (i) when R.sub.8 is >O or >S then R.sub.29 is lower alkyl or arylalkyl, and (ii) when R.sub.29 is hydrogen, lower alkyl, or arylalkyl then R.sub.3 is absent.
R.sub.30 is selected from the group consisting of hydrogen, aryl, lower alkyl, and arylalkyl.
R.sub.31 is a group having the structure ##STR9## where m and n are integers independently selected from 0, 1 and 2.
R.sub.32 is a group having the structure ##STR10## where p and q are integers independently selected from 0, 1 and 2.
R.sub.33 is a group having the structure ##STR11## where t and v are integers independently selected from 0, 1, 2 and 3.
R.sub.34 is a group having the structure ##STR12## where r and s are integers independently selected from 0, 1, 2 and 3.
R.sub.35 is a group having the structure ##STR13## where f is and integer of 0 to 3, X is selected from >C.dbd.O and --CH.sub.2 --. R is selected from hydrogen and lower alkyl, with the provisos that (i) when f is 0, X is at C-2 and R is at C-3 or C-4; (ii) when f is 1, X is at C-2 and R is at C-3, C-4 or C-5 and C-3,4 are saturated or unsaturated; (iii) when f is 2, X is at C-2, C-3 or C-4 and R is at C-2, C-3, C-4, C-5 or C-6 when the position is unoccupied by X and C-3,4 or C-4,5 are saturated or unsaturated; and (iv) when f is 3, X is at C-2, C-3 or C-4 and R is at C-2, C-3, C-4, C-5, C-6 or C- 7 when the position is unoccupied by X and C-3,4 or C-4,5 or C-5,6 are saturated or unsaturated.
R.sub.36 is a group having the structure ##STR14## where g is an integer of from 0 to 3.
R.sub.37 is a group having the structure ##STR15## where h is 0 or 1 and j is 0 or 1 with the proviso that either h or j must be 1.
R.sub.38 is a group having the structure ##STR16##
R.sub.39 is a group having the structure ##STR17##
R.sub.40 is a divalent group having the structure ##STR18##
R.sub.41 is a divalent group having the structure ##STR19##
R.sub.42 is a divalent group having the structure ##STR20##
R.sub.43 is a divalent group having the structure ##STR21## where k is an integer of from zero to two.
R.sub.1 and R.sub.2, taken together, optionally may represent a group selected from aryl, heterocyclic, or hydrogen.
R.sub.6 and R.sub.7 ; R.sub.9 and R.sub.10 ; R.sub.12 and R.sub.13 ; R.sub.15 and R.sub.16 ; R.sub.18 and R.sub.19 ; R.sub.21 and R.sub.22 ; and R.sub.24 and R.sub.25 ; each pair taken together, may optionally and independently represent a group selected from >CH.sub.2, --(CH.sub.2).sub.3 --, --CH.dbd.CH--, --C.tbd.C--, --C(.dbd.CH.sub.2)CH.sub.2 --, --CH(OH)CH.sub.2 --, --C(O)O--, --C(O)S--, --CH.sub.2 C(O)O--, --CH.sub.2 C(O)S--, --CH.sub.2 O--, --CH.sub.2 S--, and --NHC(O)--; with the provisos that (i) when R.sub.5 is >NR.sub.203 or >C.dbd.CR.sub.205 R.sub.206, R.sub.6 and R.sub.7, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (ii) when R.sub.8 is >NR.sub.213 or >C.dbd.CR.sub.215 R.sub.216, R.sub.9 and R.sub.10, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (iii) when R.sub.11 is >NR.sub.223 or >C.dbd.CR.sub.225 R.sub.226, R.sub.12 and R.sub.13, taken together represent --CONH-- or --CONCH.sub.3 --; (iv) when R.sub.14 is >NR.sub.233 or >C.dbd.CR.sub.235 R.sub.236, R.sub.15 and R.sub.16, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (v) when R.sub.17 is >NR.sub.303 or >C.dbd.CR.sub.305 R.sub.306, R.sub.18 and R.sub.19, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (vi) when R.sub.20 is >NR.sub.313 or >C.dbd.CR.sub.315 R.sub.316, R.sub.21 and R.sub.22, taken together, represent --CONH-- or --CONCH.sub.3 --; (vii) when R.sub.23 is >NR.sub.323 or >C.dbd.CR.sub.325 R.sub.326, R.sub.24 and R.sub.25, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --.
R.sub.29 and R.sub.30, taken together, optionally represent a group selected from hydrogen, hydroxy, or alkoxy, with the proviso that when R.sub.28 is >O or >S then R.sub.29 and R.sub.30, taken together, represent hydrogen.
R.sub.1, R.sub.2 and R.sub.3, taken together, optionally represent a group selected from lower alkyl, arylalkyl, alkenyl, aryl, hydroxy, alkoxy, hydrogen, an N-terminal protecting group or peptide fragment of 1-8 residues similarly protected wherein each of the amino acids comprising the peptide fragment is independently selected from the 20 naturally occuring amino acids.
R.sub.1, R.sub.2, R.sub.3 and R.sub.4, taken together, optionally represent a group selected from hydrogen, lower alkyl, arylalkyl, aryl, heterocyclic, or H.sub.2 NC(O)--, with the proviso that when R.sub.5 is >CH.sub.2 then R.sub.1, R.sub.2, R.sub.3 and R.sub.4, taken together, may not be hydrogen.
R.sub.27, R.sub.28, R.sub.29 and R.sub.30, taken together, optionally represent a group selected from hydrogen, lower alkyl, aryl, or arylalkyl.
R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5, taken together, optionally represent an aryl or heterocyclic group.
R.sub.95, R.sub.96, R.sub.205, R.sub.206, R.sub.215, R.sub.216, R.sub.225, R.sub.226, R.sub.235, R.sub.236, R.sub.305, R.sub.306, R.sub.315, R.sub.316, R.sub.335 and R.sub.336 are independently selected from the group consisting of hydrogen, lower alkyl, aryl, arylalkyl, (cycloalkyl)alkyl, amidoalkyl, (carboxyamido)alkyl, ureidoalkyl, (heterocyclic)alkyl, and halosubstituted alkyl.
R.sub.99, R.sub.202, R.sub.211, R.sub.231, R.sub.302, R.sub.311, R.sub.321 and R.sub.331 are independently selected from hydrogen and lower alkyl.
R.sub.100 is selected from the group consisting of hydrogen, lower alkyl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, (alkylamino)alkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, arylalkoxy, and sulfhydrylalkyl.
R.sub.201 is selected from the group consisting of hydrogen, lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, (carboxyhydrazino)alkyl, ureidoalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl.
R.sub.203, R.sub.213, R.sub.223, R.sub.303, and R.sub.313 are independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, (carboxyhydrazino)alkyl, ureidoalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, (thioarylalkoxy)alkyl, or protected sulfhydrylalkyl with the proviso that none of the groups R.sub.203, R.sub.213, R.sub.223, R.sub.233, R.sub.303, or R.sub.313 may be a vinyl group or have a heteroatom directly attached to the nitrogen or separated from it by one methylene unit.
R.sub.210 is hydrogen, lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, ureidoalkyl, (carboxyhydrazino)alkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, or halosubstituted alkyl.
R.sub.220, R.sub.230, R.sub.301, R.sub.310, and R.sub.330 are independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, (carboxyhydrazino)alkyl, ureidoalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, or halosubstituted alkyl.
R.sub.320 and R.sub.323 are selected from the group consisting of hydrogen, lower alkyl, alkenyl, aryl, benzyl, (cycloalkyl)alkyl, -(alkylene)-C(O)NR.sub.340 R.sub.341, -(alkylene)-NR.sub.342 R.sub.343, -(alkylene)-NR.sub.344 C(O)R.sub.345, hydroxyalkyl, -(alkylene)-NR.sub.342 R.sub.343, -(alkylene)-NR.sub.344 C(O)R.sub.345, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyhydrazino)alkyl, ureidoalkyl, heterocyclic substituted methyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl, where R.sub.340, R.sub.341, R.sub.342, and R.sub.343 are independently selected from hydrogen and lower alkyl, and R.sub.344 and R.sub.345 are independently selected from hydrogen, lower alkyl, and halosubstituted lower alkyl, with the proviso that R.sub.323 may not be a vinyl group or have a heteroatom directly attached to the nitrogen or separated from it by one methylene unit.
R.sub.325 and R.sub.326 are independently selected from the group consisting of hydrogen, lower alkyl, aryl, (cycloalkyl)alkyl, -(alkylene)-NR.sub.344 C(O)R.sub.345, (carboxyamido)alkyl, ureidoalkyl, (heterocyclic)alkyl, and halosubstituted alkyl, where R.sub.344 and R.sub.345 are as defined above.
R.sub.201 and R.sub.202, R.sub.210 and R.sub.211, R.sub.220 and R.sub.221, R.sub.230 and R.sub.231, R.sub.301 and R.sub.302, R.sub.310 and R.sub.311, R.sub.320 and R.sub.321, and R.sub.330 and R.sub.331, each pair taken together, independently may optionally represent --(CH.sub.2).sub.z -- where z is an integer of from 2 to 6.
All of the foregoing definitions are with the provisos that, in the compounds of the present invention, (i) when more than one sulfhydrylalkyl is present in the compound, the compound exists in the oxidized disulfide form producing a cyclic molecule, or the two sulfhydryl moieties are connected by a C.sub.2 to C.sub.8 alkylene chain and (ii) when the compound contains a free amino group and carboxyl group, they can be cyclized to give the corresponding lactam.
DETAILED DESCRIPTION
As discussed above, C5a is the most active of a class of biologically active peptides which serves to amplify and exacerbate inflammation. While C5a contains 74 amino acid residues, it has been found in accordance with the present invention that oligopeptides containing as few as eight amino acid residues are also actively bound by C5a receptors. Moreover, it has been found that peptidomimetic compounds (i.e. compounds which mimic the activity of peptides) in which certain groups replace the .alpha.-carbon, carbonyl group, and amide-nitrogen group of the individual amino acids in oligopeptides are also actively bound by C5a receptors.
The chemical structures of the compounds of the present invention are best understood by reference to the following structural formula in which it is understood that the segments are joined serially at the free valence bonds to form the compound A-B-D-E-G-J-L-M-Q-T. ##STR22##
As used throughout this specification and the appended claims, the following terms have the meanings specified.
The term "alkyl" as used herein refers to monovalent straight chain or branched chain groups of 1 to 12 to carbon atoms, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
The term "lower alkyl" as used herein refers to straight or branched chain alkyl groups containing from 1 to 8 carbon atoms including but not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, 2-methylhexyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.
The term "alkylene" as used herein refers to divalent groups of from one to twelve carbon atoms derived by the removal of two hydrogen atoms from straight or branched saturated hydrocarbons. Examples include --CH.sub.2 --, --CH(CH.sub.3)--, --C(CH.sub.3).sub.2 --, --CH(C.sub.2 H.sub.5)--, --CH.sub.2 CH.sub.2 --, --CH.sub.2 CH(CH.sub.3)--, --C(CH.sub.3).sub.2 C(CH.sub.3).sub.2 --, --CH.sub.2 CH.sub.2 CH.sub.2 -- and the like.
The term "alkenyl" as used herein refers to straight or branched chain groups of 2 to 12 carbon atoms containing a carbon-carbon double bond, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like.
The term "halosubstituted alkyl" refers to an alkyl group as described above substituted with one or more halogens, including, but not limited to chloromethyl, trifluoromethyl, 2,2,2-trichloroethyl, and the like. The terms "halo" and "halogen" are used herein to mean groups derived from the elements fluorine, chlorine, bromine, or iodine.
The term "cycloalkyl" as used herein refers to cyclic groups, of 3 to 8 carbons, including, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
The term "(cycloalkyl)alkyl" as used herein refers to a cycloalkyl group appended to a lower alkyl group, including, but not limited to cyclohexylmethyl and cyclohexylethyl.
The term "alkoxy" as used herein refers to an alkyl group as defined above, attached to the remainder of the molecule through an oxygen atom. Alkoxy groups include, for example, methoxy, ethoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, and the like.
The term "sulfhydrylalkyl" as used herein refers to a --SH group appended to a lower alkyl group, as previously defined.
The term "protected sulfhydrylalkyl" refers to a sulfhydrylalkyl group, as previously defined, which has been transformed to the corresponding S-acetamidomethyl (S-Acm) or other similar protecting group, including, but not limited to S-phenacetamidomethyl.
The term "thioalkoxy" as used herein refers to an alkyl group, as previously defined, attached to the remainder of the molecule through a sulfur atom. Examples of thioalkoxy groups include, but are not limited to, thiomethoxy, thioethoxy, thioisopropoxy, n-thiobutoxy, sec-thiobutoxy, isothiobutoxy, tert-thiobutoxy and the like.
The term "(thioalkoxy)alkyl" as used herein refers to a thioalkoxy group, as just defined, appended to a lower alkyl group.
The term "(thioarylalkoxy)alkyl" as used herein refers to a group of the structure R.sub.420 --S-- appended to a lower alkyl where R.sub.420 is an arylalkyl group as defined below.
The term "aryl" as used herein refers to substituted and unsubstituted carbocyclic aromatic groups including, but not limited to phenyl, 1- or 2-naphthyl, fluorenyl, (1,2)-dihydronaphthyl, (1,2,3,4)-tetrahydronaphthyl, indenyl, indanyl, and the like, wherein the aryl group may be substituted with 1, 2, or 3 substituents independently selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy aroyl and halosubstituted alkyl.
The term "arylalkyl" as used herein refers to an aryl group, as previously defined, appended to an alkyl group, including, but not limited to benzyl, 1- and 2-naphthylmethyl, halobenzyl, alkoxybenzyl, hydroxybenzyl, aminobenzyl, nitrobenzyl, guanidinobenzyl, phenylmethyl(benzyl), 1-phenylethyl, 2-phenylethyl, 1-naphthylethyl, and the like.
The term "benzyl" as used herein refers specifically to to phenyl substituted methyl in which the phenyl group may be substituted with 1, 2, or 3 substituents independently selected from halo, nitro, cyano, alkyl of from one to twelve carbon atoms, alkoxy, aroyl, and halosubstituted alkyl, and the like.
The term "aryloxy" as used herein refers to an aryl group as previously defined, attached to the parent molecular moiety through an oxygen atom. Aryloxy includes, but is not limited to phenoxy, 1-naphthoxy, 2-naphthoxy and the like.
The term "arylalkoxy" as used herein refers to an arylalkyl group as previously defined, attached to the parent molecular moiety through an oxygen atom. Arylalkoxy includes, but is not limited to benzyloxy, 2-phenethyloxy, 1-naphthylmethyloxy and the like.
The term "aroyl" as used herein refers to an aryl group as defined above, attached to the parent molecule through a carbonyl group. Examples include benzoyl and substituted benzoyl.
The term "alkylamino" as used herein refers to a group having the structure --NH(alkyl) where the alkyl portion is as defined above. Alkylamino groups include, for example, methylamino, ethylamino, isopropylamino and the like.
The term "dialkylamino" as used herein refers to a group having the structure --N(alkyl)(alkyl) where the two alkyl groups may be the same or different and are as previously defined.
The term "aminoalkyl" as used herein refers to a group having the structure --NR.sub.342 R.sub.343 appended to a lower alkyl group, as previously defined. The groups R.sub.342 and R.sub.343 are independently selected from hydrogen, lower alkyl, aryl and arylalkyl. Additionally, R.sub.342 and R.sub.343 taken together, may optionally be --(CH.sub.2).sub.mm -- where mm is an integer of from 2 to 6.
The term "amidoalkyl" as used herein refers to a group having the structure --NR.sub.344 C(O)R.sub.345 appended to a lower alkyl group, as previously defined. The groups R.sub.344 and R.sub.345 are independently selected from hydrogen, lower alkyl, aryl, arylalkyl, and halosubstituted alkyl. Additionally, R.sub.344 and R.sub.345 taken together may optionally be --(CH.sub.2).sub.kk -- where kk is an integer of from 2 to 6.
The term "(aminothioalkoxy)alkyl" as used herein refers to H.sub.2 N--Rx--S--Ry-- where Rx and Ry are alkylene groups, as previously defined, and may be the same or different.
The term "carboxyalkyl" as used herein refers to a carboxyl group, --CO.sub.2 H, appended to a lower alkyl group, as previously defined.
The term "(carboxyamido)alkyl" as used herein refers to a group of the formula --C(O)NR.sub.340 R.sub.341, appended to a lower alkyl group, as previously defined. The groups R.sub.340 and R.sub.341 are independently selected from hydrogen, lower alkyl, aryl and arylalkyl. Alternatively, R.sub.340 and R.sub.341 taken together may optionally be --(CH.sub.2).sub.pp -- wherein pp is an integer of from 2 to 6.
The term "(carboxyhydrazino)alkyl" as used herein refers to a group having the structure --C(O)NR.sub.425 NHR.sub.430 appended to a lower alkyl group, as previously defined. The groups R.sub.425 and R.sub.430 are independently selected from hydrogen, lower alkyl, aryl and arylalkyl.
The term "guanidinoalkyl" as used herein refers to a group of the structure --NR.sub.346 C(.dbd.NR.sub.347)NHR.sub.348 appended to a lower alkyl group, as previously defined. R.sub.346, R.sub.347, and R.sub.348 are independently selected from hydrogen, lower alkyl, and aryl.
The term "ureidoalkyl" as used herein refers to a group having the structure --NHC(O)NH.sub.2 appended to a lower alkyl group, as previously defined.
The term "heterocyclic" as used herein refers to any 5- or 6-membered ring containing from one to three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the 5-membered ring has 0 to 2 double bonds and the 6-membered ring has 0 to 3 double bonds, wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, wherein the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring. Representative heterocycles include, but are not limited to pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazoyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, indolyl, quinolinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, and benzothienyl.
The term "(heterocyclic)alkyl" as used herein refers to a heterocyclic group, as previously defined, appended to an alkyl group as previously defined.
The term "hydroxyalkyl" as used herein refers to --OH appended to a lower alkyl group.
The term "naturally occuring amino acid" refers to an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
The term "N-terminal protecting group" refers to those groups intended to protect the N-terminus against undesirable reactions during synthetic procedures or to prevent the attack of exopeptidases on the final compounds or to increase the solubility of the final compounds and includes, but is not limited to acyl, acetyl, pivaloyl, tert-butylacetyl, tert-butyloxycarbonyl (Boc), carbobenzyloxycarbonyl (Cbz), benzoyl groups or an L- or D-aminoacyl residue, which may itself be N-protected similarly.
The term "anaphylatoxin" is used herein to mean C5a, C4a, C3a, or the corresponding des-Arg degradation products.
The term "pharmaceutically acceptable salt" refers to non-toxic acid addition salts such as salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, malic acid, tartaric acid, citric acid, succinic acid or malonic acid. Other pharmaceutically acceptable salts include inorganic nitrate, sulfate, acetate, malate, formate, lactate, tartrate, succinate, citrate, p-toluenesulfonate, and the like, including, but not limited to cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
Examples of pharmaceutically acceptable, non-toxic esters of the compounds of this invention include C.sub.1 to C.sub.6 alkyl esters wherein the alkyl group is straight or branched chain. Acceptable esters also include C.sub.5 to C.sub.7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C.sub.1 to C.sub.4 alkyl esters are preferred. Esters of the compound of formula I may be prepared according to conventional methods.
Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary C.sub.1 to C.sub.6 alkyl amines and secondary C.sub.1 to C.sub.6 dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5 or 6 membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C.sub.1 to C.sub.3 alkyl primary amides and C.sub.1 to C.sub.2 dialkyl secondary amides are preferred. Amides of the compound of formula I may be prepared according to conventional methods.
Numerous asymmetric centers may exist in the compounds of the present invention. The present invention contemplates the various stereoisomers and mixtures thereof. In particular, chiral centers Can exist at R.sub.2, R.sub.5, R.sub.8, R.sub.11, R.sub.14, R.sub.17, R.sub.20, R.sub.23 and R.sub.26. When these groups comprise the .alpha.-carbon atom of an .alpha.-amino acid, the natural configuration is preferred. However, compounds of the present invention containing up to three .alpha.-amino acid residues of non-natural configuration have also been found to be effective as modulators of anaphylotoxin activity.
Particular stereoisomers are prepared by selecting the starting amino acids or amino acid analogs having the desired stereochemistry and reacting these starting materials by the methods detailed below. Starting compounds of particular stereochemistry are either commercially available or are made by the methods detailed below and resolved by techniques well known in the organic chemical arts.
One class of preferred compounds of the present invention are those in which the groups R.sub.4, R.sub.7, R.sub.10, R.sub.13, R.sub.16, R.sub.19, R.sub.22, and R.sub.25 are independently selected from >NH and >N--(lower alkyl).
In another class of preferred compounds of the present invention, the groups R.sub.6, R.sub.9, R.sub.12, R.sub.15, R.sub.18, R.sub.21, R.sub.24, and R.sub.27 are independently selected from >C.dbd.O and >CH.sub.2.
The group R.sub.5 is preferably selected from >CR.sub.201 R.sub.202 ; >NR.sub.203 ; >C.dbd.CR.sub.205 R.sub.206, existing in the Z- or E-configuration; and substituted cyclopropyl of the formula ##STR23## where R.sub.201 is selected from lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, amidoalkyl, (carboxyamido)alkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl. R.sub.202 and R.sub.205 are selected from the group consisting of hydrogen and lower alkyl; R.sub.203 is selected from the group consisting of lower alkyl, alkenyl, arylalkyl, (cycloalkyl)alkyl, amidoalkyl, (carboxyamido)alkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, (thioarylalkoxy)alkyl, and protected sulfhydrylalkyl, with the proviso that R.sub.203 may not be a vinyl group or have a heteroatom directly attached to the nitrogen or separated from it by one methylene group. R.sub.206 is selected from the group consisting of lower alkyl; aryl; arylalkyl; (cycloalkyl)alkyl; amidoalkyl; (carboxyamido)alkyl; (heterocyclic)alkyl; and halosubstituted alkyl.
R.sub.8 is preferebly selected from the group consisting of >CR.sub.210 R.sub.211 ; >NR.sub.213 ; >C.dbd.CR.sub.215 R.sub.216 ; and substituted cyclopropyl of the formula ##STR24## R.sub.210 is selected from the group consisting of arylalkyl; aminoalkyl; guanidinoalkyl; (heterocyclic)alkyl; (aminothioalkoxy)alkyl. R.sub.211 and R.sub.215 selected from hydrogen and lower alkyl; R.sub.213 is selected from the group consisting of arylalkyl; aminoalkyl; guanidinoalkyl; (heterocyclic)alkyl; and (aminothioalkoxy)alkyl; with the proviso that R.sub.213 may not have a herteroatom directly attached to the nitrogen or separated from it by one methylene unit; and R.sub.216 is selected from arylalkyl and (heterocyclic)alkyl.
R.sub.26 is preferably selected from the group consisting of >CR.sub.330 R.sub.331 ; >C.dbd.CR.sub.335 R.sub.336, existing in either the Z- or E-configuration; and substituted cyclopropyl of the formula ##STR25## where R.sub.335 is selected from hydrogen and lower alkyl. R.sub.336 is selected from arylalkyl and (heterocyclic)alkyl; R.sub.330 is selected from the group consisting of arylalkyl, aminoalkyl, guanidinoalkyl, (heterocyclic)alkyl and (aminothioalkoxy)alkyl; and R.sub.331 is hydrogen or lower alkyl.
METHOD OF TREATMENT
The compounds of the present invention serve to modulate the activity of anaphylatoxin. Certain compounds of the present invention function as anaphylatoxin antagonists, while others function as agonists. The antagonist compounds of the present invention block the anaphylatoxin receptor and prevent anaphylatoxin activity, which makes those compounds useful in the treatment and prevention of injurious conditions or diseases in which anaphylatoxin may be involved. Disease states in which anaphylatoxin is involved include asthma, bronchial allergy, chronic inflammation, systemic lupus erythematosus, vasculitis, serum sickness, angioedema, rheumatoid arthritis, osteoarthritis, gout, bullous skin diseases, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, immune complex-mediated glomerulonephritis, psoriasis, allergic rhinitis, adult respiratory distress syndrome, acute pulmonary disorders, endotoxin shock, hepatic cirrhosis, pancreatitis, inflammatory bowel diseases (including Crohn's disease and ulcerative colitis), thermal injury, Gram-negative sepsis, necrosis in myocardial infarction, leukophoresis, exposure to medical devices (including but not limited to hemodialyzer membranes and extracorpeal blood circulation equipment), chronic hepatitis, transplant rejection, post-viral encephalopathies, and/or ischemia induced myocardial or brain injury. These compounds may also be used as prophylactics for such conditions as shock accompanying Dengue fever. In addition, a combination of antibiotic and anti-inflammatory agent such as corticosteroids (e.g., methylprednisolone) and one or more of the above mentioned compounds may be employed.
Certain compounds of the invention are useful therapeutic agents because of their ability to mimic or promote anaphylatoxin activity and are therefore useful in stimulating the inflammatory response and immune response in mammals who are deficient in this regard. These agonist compounds may be used to assist the body in building its defense mechanism against invasion by infectious microorganisms or other stress. Interaction by these agonists at the anaphylatoxin receptor makes them useful in treating conditions or diseases including, but not limited to cancers (including but not limited lung carcinoma), immunodeficiency diseases, and severe infections.
In some cases this will involve preventing the underlying cause of the disease state and in other cases, while the underlying disease will not be affected, the compounds of this invention will have the benefit of ameliorating the symptoms or preventing the manifestations of the disease.
The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants and vehicles as desired.
The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intrasternal, intra-arterial injection or infusion techniques, without limitation. The term "topically" encompasses administration rectally and by inhalation spray, as well as by the more common routes of the skin and the mucous membranes of the mouth and nose.
Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
Generally dosage levels of about 0.001 mg to about 100 mg, more typically from about 0.1 mg to about 20 mg, of active compound per kilogram of body weight per day are administered daily to a mammalian host. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.
FORMULATION OF PHARMACEUTICAL COMPOSITION
Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous cariers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like, Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay abdorption such as aluminum monostearate and gelatin.
If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternaryammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Dosage forms for topical administration of a compound cf this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
ANAPHYLATOXIN RECEPTOR BINDING KI DETERMINATION
Specific inhibition of C5a binding activity of representative compounds of the present invention was measured using 0.03-1 nM .sup.125 I-C5a with 2.5-25 .mu.g/mL of purified PMNL membrane fragments (Borregaard, N.; Heiple, J. M.; Simons, E. R.; and Clark, R. A. J. Cell. Biol. 1983, 97, 52-61.). Free and membrane-bound ligand were separated by filtration. Binding potencies for representative examples of compounds of this invention are listed in Table 1.
SYNTHESIS OF THE COMPOUNDS
The novel compounds and salts thereof of the invention can be utilized effectively as therapeutic agents. Accordingly, the present invention further relates to therapeutic compositions comprising a novel compound having the general formula I or salts thereof as an active component.
The compounds of the invention may be prepared by a synthetic method of elongation of a peptide chain through condensation of one amino acid by one, or by a method of coupling fragments consisting of two or several amino acids, or by a combination of these methods in accordance with conventional peptide synthesis methods.
The condensation of two amino acids, the condensation of an amino acid with a peptide or the condensation of one peptide with another peptide may be effected in accordance with conventional condensation methods such as azide method, mixed acid anhydride method, symmetrical anhydride method, DCC (dicyclohexylcarbodiimide) method, active ester method (p-nitrophenyl ester method, N-hydroxysuccinimide ester method, cyanomethyl ester method and the like), Woodward reagent K method, DCC-HOBT(1-hydroxy-benzotriazole) method and the like. These condensation reactions may be done by either solution methods or solid phase synthetic methods. When the peptide chain is elongated by the solid phase method, the C-terminal amino acid is linked to an insoluble carrier. As the insoluble carrier, any that can produce a detachable bond by reacting with a carboxyl group in a C-terminal amino acid may be used, and the examples thereof involve, for example, halomethyl resins such as chloromethyl resin, bromomethyl resin and the like, hydroxy-methyl resin, benzhydrylamine resin, and t-alkyloxycarbonyl hydrazide resin.
As conventional polypeptide synthesis, branched chain amino and carboxyl groups at alpha and omega positions in amino acids may be protected/deprotected if necessary. The protecting groups for amino groups which can be used involve, for example, benzyloxycarbonyl (Z), o-chlorobenzyloxycarbonyl ((2-C1)Z), p-nitrobenzyloxycarbonyl (Z(NO.sub.2)), p-methoxybenzyloxycarbonyl (Z(OMe)), t-butoxycarbonyl (Boc), t-amyloxycarbonyl (Aoc), isobornyloxycarbonyl, admantyloxycarbonyl, 2-(4-biphenyl)-2-propyloxycarbonyl (Bpoc), 9-fluorenyl-methoxycarbonyl (Fmoc), methylsulfonylethoxycarbonyl (Msc), trifluoroacetyl, phthalyl, formyl, 2-nitrophenylsulfenyl (Nps), diphenylphosphinothioyl (Ppt), and dimethylphosphinothioyl (Mpt).
The examples of protecting groups for carboxyl groups involve, for example, benzyl ester (OBn), cyclohexyl ester, 4-nitrobenzyl ester (OBnNO.sub.2), t-butyl ester (OtBu), 4-picolyl ester (OPic) and the like.
In the course of the synthesis of the present novel compounds, specific amino acids having functional groups other than amino and carboxyl groups in the branched chain such as arginine, cysteine, serine, and the like may be protected, if necessary, with suitable protecting group. It is preferable that for example, the guanidino group (N.sup.G) in arginine may be protected with nitro, p-toluenesulfonyl (Tos), benzyloxycarbonyl (Z), adamantyloxycarbonyl (Adoc), p-methoxybenzenesulfonyl, 4-methoxy-2,6-dimethylbenzenesulfonyl (Mds), 1,3,5-trimethylphenylsulfonyl (Mts) and the like, and the thiol group in cysteine may be protected with benzyl, p-methoxybenzyl, triphenylmethyl, acetamidomethyl, ethylcarbamyl, 4-methylbenzyl (4-MeBn), 2,4,6-trimethylbenzyl (Tmb) and the like, and the hydroxyl group in serine may be protected with benzyl (Bn), t-butyl, acetyl, tetrahydropyranyl and the like.
N-Acetylated peptides were prepared in analogy to Example 99. The following literature procedures were used to prepare N-alkyl- or N,N-dialkyl-amino acid derivatives. Lovett, J. A.; Portoghese, P. J. Med. Chem. 1987, 30, 1144-1149. Borch, R. F.; Hassid, A. I. J. Org. Chem. 1972, 37, 1673-1674. Hansen, D. W.; Pilipauskas, D. J. Org. Chem. 1985, 50, 945-950. Grieco, P. A.; Bashas, A. J. Org. Chem. 1987, 52, 5746-5749. Shuman, R. T.; Smithwick, E. L.; Smiley, D. L.; Brooke, G. S.; Gesellchen, P. D. "Peptide: Structure and Function", Proceedings of the Eighth American Peptide Symposium, 1984; p 143-146. Cheung, S. T.; Benoiton, N. L. Can. J. Chem. 1977, 55, 906-910. These reactions were carried out either on the elongated peptide-resin or on amino acid derivatives and then incorporated into the peptide-resin.
The following literature procedures were used to prepare (2'S,3S)-3-amino-2-oxo-1-pyrrolidine-(2'-(4'-methyl)}-pentanoic acid, (2'R,3S)-3-amino-2-oxo-1-pyrrolidine-(2'-(4'-methyl)}-pentanoic acid, and (2'R/S,3S)-3-amino-2-oxo-1-azepine-2'-pentanoic acid: Freidinger, R. M.; Perlow, D. S.; Veber, D. F. J. Org. Chem. 1982, 47, 104-109. The preparation of (2R,S)-2-amino-5-phenylpentanoic acid is described in: Greenstein, J. P.; Winitz, M. "Chemistry of the Amino Acids"; John Wiley and Sons, Inc.: New York, 1961; vol III, p.2387. Perhydroindolecarboxylic acid was synthesized according to the following procedure: Vincent, M.; Remond, G.; Portevin, B.; Serkiz, B.; Laubie, M. Tetrahedron Lett. 1982, 23, 1677-1682.
(2S)-2-Amino-4-cyclohexylbutanoic acid: A solution of (2S)-2-amino-4-phenylbutanoic acid (5 g) in 10% HOAc-H.sub.2 O (50 mL) was hydrogenated at room temperature at 5 atms with platinum oxide (0.1 g). Removal of catalyst by filtration and evaporation yielded 4.9 g of product. 3-(2'-Perhydronaphthyl)alanine and 3-(1'-perhydronaphthyl)alanine were prepared similarly from L-3-(2'-naphthyl)alanine and L-3-(1'-naphthyl)alanine, respectively.
The following literature procedures were used to prepare N-guanidino substituted arginine derivatives: Mathias, L. J., Synthesis 1979, 561-576; Maryanoff, C. A.; Stanzione, R. C.; Plampin; J. M.; Mills, J. E. J. Org. Chem. 1986, 51, 1882-1884; Nestor, J. J.; Ho, T. L.;Simpson, R. A.; Horner, B. L.; Jones, G. H.; McRae, G. I.; Vickery, B. H. J. Med. Chem. 1982, 25, 795-801. The obtained arginine derivatives were attached to Merrifield resin as described in: Stewart, J. M.; Young, J. D."Solid Phase Peptide Synthesis", 2nd edition; Pierce Chemical Co.: Rockford, Ill., 1984; p 71-72. The amino acid resin obtained was used to construct the peptide, followed by cleavage and purification to yield the desired peptide analog.
The following fragments are prepared as described in the literature: ##STR26##
References
1. Fiegel, M. J. Am. Chem. Soc. 1986, 108, 191.
2. Kemp, D. S.; McNamara, P. E. J. Org. Chem. 1985, 50, 5834.
3. Belanger, P. C.; Dufresne, C.; Scheigetz, J.; Yang, R. N.; Springer, J. P.; Dmitrienko, G. I. Can. J. Chem. 1982, 60, 1019.
4. Krstenansky, J. L.; Baranowdki, R. L.; Currie, B. L. Biochem. Biophys. Res. Commun. 1982, 109, 1368.
5. Attwood, M. R.; Francis, R. J.; Hassall, C. H.; Krohn, A.; Lawton, G.; Natoff, I. L.; Nixon, J. S.; Redshaw, S.; Thomas, W. A. FEBS Lett. 1984, 165, 201.
6. (a)Nagai, U.; Sato, K. Tetrahedron Lett. 1985, 647. (b)Baldwin, J.; Lee, E. Tetrahedron Lett. 1986,42, 6551.
The compounds of the invention were prepared by standard solid phase peptide synthesis conditions as described in "Solid Phase Peptide Synthesis" by J. M. Stewart and J. D. Young, Second Edition (1984) and illustrated in Examples 1 and 2 in the experimental section.
The compounds of the invention may also be prepared by partial solid phase synthesis, fragment condensation methods and classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
The standard chirality descriptors "R" and "S" are used to indicate an isomerically pure center, "RS" to indicate a mixture, and "R/S" to indicate a single pure isomer of undetermined configuration. The descriptor ".+-." refers to a d,l mixture of amino acids at the indicated residue. The descriptor .PSI.{X} indicates the group, X, that is a replacement for the standard peptide bond, --C(O)NH--. The descriptor "*" or "**" when written in a chemical name indicates the site of a disulfide or amide linkage, respectively.
The foregoing may be better understood by reference to the following examples which are provided for illustration and not limitation of the practice of the invention. Unless otherwise indicated, the standard peptide methods described above and in examples 1 and 2 were used to assemble the different products, using the precursors indicated by the specific peptide sequence. The product was at least 95% pure, and gave NMR and mass spectra consistent with the proposed structure.
EXAMPLE 1
H-Phenylalanyl-Lysyl(N-epsilon-Cbz)-Alanyl-{(2S)-2-Amino-3-cyclohexylpropan oyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl)-Leucyl-D-Alanyl-Arginyl(N-guanidi no-Tos)-Merrifield Resin
Boc-Arg(N-guanidino-Tos)-Merrifield resin (0.4-1.0 g) was placed in a solid phase peptide synthesis vessel and amino acids were attached to the resin sequentially in the following order: Boc-D-Alanine, Boc-Leucine, Boc-(2S)-2-Amino-3-cyclohexylpropanoic acid, Boc-(2S)-2-Amino-3-cyclohexylpropanoic acid, Boc-Alanine, (N-alpha-Boc-N-epsilon-Cbz)Lysine, Boc-Phenylalanine, according to the protocol outlined in Agenda A to yield the protected peptide resin: H-Phenylalanyl-Lysyl(N-epsilon-Cbz)-Alanyl-{(2S)-2-Amino-3-cyclohexylpropa noyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-D-Alanyl-Arginyl(N-guanid ino-Tos)-Merrifield resin. Following the synthesis, the protected peptide resin was removed from the reaction vessel by washing the resin three times with 20 mL DMF into a 30-60 mL sintered glass funnel, followed by washing the resin three times with 20 mL methylene chloride. The resin was dried at least five hours, then weighed.
Agenda A
1. Deblock : 45% trifluoroacetic acid (TFA) in methylene chloride containing 2.5% anisole (v/v/v).
2. Neutralization : 10% diisopropylethylamine (DIEA) in methylene chloride (v/v)
3. Single Coupling : 0.2-0.4M Boc-amino acid derivative in N,N-dimethylformamide (DMF), 0.2-0.4M diisopropylcarbodiimide (DIC) in methylene chloride, reaction time, 60 minutes.
4. Resin base washing : 10% DIEA in methylene chloride (v/v).
5. Single Coupling repeated : same as Step 3.
6. Go to next amino acid residue (go back to Step 1).
7. Upon attachment of the final amino acid to the growing peptide chain, the protecting group (t-Boc) is removed as in Step 1.
EXAMPLE 2
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
The protected peptide resin of Example 1 (0.6 g) was treated with 1.0 mL anisole and 10 mL hydrogen fluoride (HF) for 60 minutes at 0.degree. C. The HF and anisole were removed in vacuo at 0.degree. C., and the mixture of the peptide and resin was washed with diethyl ether (2.times.25 mL). The crude peptide was extracted from the mixture by treatment with portions of 20% aqueous acetic acid (4.times.25 mL), lyophilized to a dry amorphous powder, and purified by high performance liquid chromatography (HPLC) {column: 21.4 mm ID.times.25 cm or 41.4 mm ID.times.25 cm, Dynamax (Rainin), 8 um silica, C18 reverse-phase column}. The sample was purified by gradient elution (from 20 to 60% (80% acetonitrile in water with 0.1% trifluoroacetic acid)} at a flow rate of 15-45 mL/min. FAB.sup.+ MS: (M+H).sup.+ =1011; Amino Acid Anal.: Phe (0.91), Lys (1.01), Ala (2.06), Cha (1.96), Leu (0.91), Arg (1.04)
EXAMPLE 3
Ac-Histidyl-Lysyl-Asparaginyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Asx (0.98), Glx (1.07), Gly (0.97), Met (0.96), Leu (1.05), His (0.97), Lys (0.98), Arg (1.04)
EXAMPLE 4
Ac-Histidyl-Lysyl-Aspartyl-Methionyl-Phenylalanyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1045
EXAMPLE 5
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-(Fragment-1)-Leucyl-(N-Methyl )DAlanyl-Arginyl-OH
EXAMPLE 6
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Aminohexanoyl}-{(2S)-2-Aminohexanoyl}-{( 2S)-2-Aminohexanoyl}-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =993; Amino Acid Anal.: Asx (0.96), Gly (0.98), His (0.84), Lys (1.01), Arg(1.05), Nle (3.07)
EXAMPLE 7
H-Histidyl-Lysyl-Aspartyl-Methionyl-{(2'S,3S)-3-Amino-2-oxo-1-pyrrolidine-{ 2'-(4'-methyl))-pentanoyl}-Glycyl-Arginyl-OH FAB.sup.+ MS: (M+H).sup.+ =939
EXAMPLE 8
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-Cyclohexylpropanoyl]-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-3-Aminopropanoyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087; Amino Acid Anal.: Asx (1.01), Leu (0.99), Cha (1.98), His (0.93), Lys (1.01), Arg(1.03)
EXAMPLE 9
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-(Fragment-2)-Arginyl-OH
EXAMPLE 10
Ac-Histidyl-Lysyl-Aspartyl-Methionyl-Threonyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =999; Amino Acid Anal.: Asx (0.96), Thr (0.78), Gly (1.02), Met (0.84), Leu (1.05), His (0.95), Lys (0.84), Arg (1.03)
EXAMPLE 11
AC-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-lsoleucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087
EXAMPLE 12
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DMethionyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1147; Amino Acid Anal.: His (1.10), Lys (0.94), Asp (0.96, Cha (1.84), Leu (1.01), Met (0.96), Arg (1.03)
EXAMPLE 13
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-Pipecolyl(.+-.)-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1127; Amino Acid Anal.: His (1.19), Lys (1.04), Asp (1.09), Cha (1.71), Leu (1.04), Arg (0.92)
EXAMPLE 14
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-(Fragment-3)-Leucyl-(N-Methyl )DAlanyl-Arginyl-OH
EXAMPLE 15
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-4-cyclohexylbutanoyl}-{(2S)-2-Amin o-4-cyclohexylbutanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1115
EXAMPLE 16
H-6-Aminohexanoyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1893
EXAMPLE 17
Ac-Histidyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino -3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1043
EXAMPLE 18
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-(Fragment-4)-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 19
Ac-Histidyl-Lysyl-Aspartyl-Cysteinyl(Acm)-Cysteinyl(Acm)-Leucyl-DAlanyl-Arg inyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1129
EXAMPLE 20
Ac-Histidyl-Lysyl-Aspartyl-DTryptophyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1120
EXAMPLE 21
Ac-Histidyl-Lysyl-Aspartyl-Methionyl-Histidyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1049
EXAMPLE 22
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-DTryptophyl -Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1120
EXAMPLE 23
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Histidyl-Le ucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1071
EXAMPLE 24
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-(Fragment-5)-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 25
Ac-Histidyl-Lysyl-Aspartyl-Cysteinyl*-Cysteinyl*-Leucyl-Alanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =985
EXAMPLE 26
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Valyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1073; Amino Acid Anal.: His (1.17), Lys (1.00), Asp (0.93), Cha (1.71), Val (1.00), Ala (0.90), Arg (0.97)
EXAMPLE 27
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DSeryl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1103; Amino Acid Anal.: His (1.06), Lys (1.19), Asp (0.83), Cha (1.93), Leu (1.04), Ser (0.50), Arg (0.91)
EXAMPLE 28
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-(Fragment-6)-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 29
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1172; Amino Acid Anal. His (1.09), Lys (0.97), Asp (0.93), Cha (1.74), Leu (0.95), Arg (1.96)
EXAMPLE 30
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2'S,3S)-3 -Amino-2-oxo-1-pyrrolidine-{2'-(4'-methyl)}-pentanoyl}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1017
EXAMPLE 31
Ac-(4-NO.sub.2)Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropan oyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1142
EXAMPLE 32
H-Phenylalanyl-{(2S)-2Amino-6-trifluoroacetamidohexanoyl}-Alanyl-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAla nyl-Arginyl-OH
EXAMPLE 33
Ac-Histidyl-Lysyl-Glutaminyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-A mino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1100
EXAMPLE 34
Ac-Histidyl-Lysyl-Cysteinyl(Acm)-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S) -2-Amino-3-cyclohexylpropanoyl}-Leucyl-DCysteinyl(Acm)-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1249
EXAMPLE 35
H-Phenylalanyl-{(2S)-2-Amino-6-formamidohexanoyl}-Alanyl-{(2S)-2-Amino-3-cy clohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Argi nyl-OH
EXAMPLE 36
Ac-Histidyl-Lysyl-Aspartyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leuc yl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1005
EXAMPLE 37
Ac-Histidyl-(N-delta-iPr)Ornithyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1114; Amino Acid Anal.: Ala (1.00), Leu (1.01), His (1.11), Cha (1.79), Arg (1.01)
EXAMPLE 38
Ac-Histidyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-NHNH.sub.2
N-Acetyl-Histidyl-Lysyl(N-epsilon-Cbz)-Asparaginyl{(2S)-2-Amino-3-cyclohexy lpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-D-Alanyl-Arginyl(N- guanidino-Tos)-OResin (0.62g) was suspended in 10 mL of N,N-dimethylformamide (DMF), and 1 mL of anhydrous hydrazine was added. The mixture was stirred at room temperature for 4 days and filtered. The resin was washed with an additional 10 mL of DMF, and the combined DMF solution was poured into 100 mL of diethylether. Upon cooling the mixture, it gradually solidified. The solid was collected by filtration, washed with 50 mL of water and dried. The dry solid obtained (approximately 160 mg) was treated with HF and anisole, as described in Example 2. After lyophilization, 153 mg of crude peptide was obtained which was purified by HPLC (Example 2) to yield 35.6 mg of pure peptide that gave NMR and mass spectra consistent with the desired product.
FAB.sup.+ MS: (M+H).sup.+ =1099
EXAMPLE 39
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-{(2S)-2-Aminopentanoyl}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1189; Amino Acid Anal.: Ala (1.00), His (1.11), Cha (1.89), Lys (0.98), Arg (1.01)
EXAMPLE 40
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-Glycyl-Glycyl-OH
EXAMPLE 41
Ac-Histidyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OCH.sub.3
FAB.sup.+ MS: (M+H).sup.+ =1100; Amino Acid Anal.: Asx (0.91), Ala (0.90), Leu (0.96), His (1.08), Cha (1.65), Lys (0.97), Arg (0.95)
EXAMPLE 42
Ac-Histidyl-Lysyl-Aspartyl-{(2R)-2-Amino-3-cyclohexylpropanoyl}-{(2R)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087; Amino Acid Anal.: Asx (0.99), Ala (0.95), Leu (1.02), His (1.07), Cha (1.80), Lys (1.03), Arg (1.02)
EXAMPLE 43
Ac-Alanyl-Arginyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1048; Amino Acid Anal.: Asx (1.01), Ala (1.94), Leu (1.02), Cha (1.88), Arg (2.08)
EXAMPLE 44
Ac-Lysyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1077; Amino Acid Anal.: Asx (0.98), Ala (0.93), Leu (1.01), Cha (1.87), Lys (2.01), Arg (1.01)
EXAMPLE 45
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-{(4R)-(4-Ethyl)Agmatine}
N-alpha-Boc-N-guanidino-Tosyl-Arginine is converted to its aldehyde which is reacted with methylenetriphenylphosphorane using a modified literature procedure (Luly, J. R.; Dellaria, J. F.; Plattner, J. J.; Soderquist, J. L.; Yi, N. J. Org. Chem. 1987, 52, 1487) followed by hydrogenation on Pd/C to yield (4R)-N-alpha-Boc-N-guanidino-Tosyl-(4-Ethyl)Agmatine. The protected peptide: N-Boc-(N-Methyl)Phenylalanyl-N-epsilon-Cbz-Lysyl-(N-Methyl)Alanyl-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Gylcyl-Leucyl-(N-Methyl)DAlanine is synthesized according to the procedure of Example No. 309. The above agmatine derivative is treated with 4N-HCl/Dioxane, and the resulting salt is coupled with the protected peptide using a DCC/HOBT mediated coupling procedure. The protecting groups are removed by treatment with liquid HF/anisole according to the procedure of Example 2.
EXAMPLE 46
H-Lysyl-Phenylalanyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1055
EXAMPLE 47
H-Phenylalanyl-Lysyl-4-Aminobutanoyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =872; Amino Acid Anal.: Phe (0.99), Lys (1.01), Gaba (0.97), Cha (0.94), Leu (1.06), Ala (1.00), Arg (1.00)
EXAMPLE 48
H-DPhenylalanyl-DLysyl-DAspartyl-DMethionyl-DGlutaminyl-DLeucyl-Arginyl-DAr ginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1093; Amino Acid Anal.: Asp (0.97), Glx (1.05), Met (0.61), Leu (1.03), Phe (0.97), Lys (0.94), Arg (2.04)
EXAMPLE 49
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-{NH(alpha)Phenethyl(R/S)}
The protected peptide: N-Boc-(N-Methyl)Phenylalanyl-N-epsilon-Boc-Lysyl-(N-Methyl)Alanyl-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Gylcyl-Leucyl-(N-Methyl)DAlanine is prepared by the method described below. The peptide chain is elongated by the same method described in Example 1, except that after N-alpha-Fmoc-N-epsilon-Boc-Lysine is coupled, the sequence is stopped at agenda A-step 5. The obtained N-alpha-Fmoc-N-epsilon-Boc-Lysyl-peptide resin is treated with DMF:piperidine (1:1) for 30 minutes at room temperature. After the peptide resin is washed with DMF and methylene chloride, the next synthetic protocol (Example 1, agenda A-step 3) is initiated with the exception that the N-terminal protecting group is not removed at the end of the synthesis. The fully protected peptide is obtained by the procedure of Example 309. The protected peptide is coupled with alphaphenethylamine using DCC/HOBT. The protecting groups are removed by treatment with 4N-HCl/dioxane to give the desired compound.
EXAMPLE 50
H-Phenylalanyl-Lysyl-Prolyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1037; Amino Acid Anal.: Phe (1.01), Lys (1.01), Pro (1.02), Cha (1.96), Leu (1.09), Ala (0.88), Arg (1.04)
EXAMPLE 51
H-Phenylalanyl-Histidyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{ (2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS (M+H).sup.+ =1148; Amino Acid Anal.: Phe (0.95), His (1.07), Lys (0.98), Ala (1.64), Cha (1.76), Leu (1.02), Arg (0.98)
EXAMPLE 52
Hydrocinnamoyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1040; Amino Acid Anal.: Lys (0.64), Asp (0.73), Cha (1.93), Leu (1.04), Ala (0.82), Arg (1.04)
EXAMPLE 53
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-{(4R)-(4-(beta-Phenethyl))Agmatine}
(4R)-N-alpha-Boc-N-guanidino-Tosyl-(4-(beta-Phenethyl))Agmatine is synthesized by the method described in Example 45 with the exception that benzyltriphenylphosphorane is used instead of methylenetriphenylphosphorane. The Boc group is removed by treatment with 4N-HCl/dioxane, and the resulting amine salt is coupled with the protected heptapeptide (cited in Example 45) using DCC/HOBT. The protecting groups are removed by treatment with liquid HF/anisole to give the desired compound.
EXAMPLE 54
H-Phenylalanyl-Lysyl-DProlyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-A mino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1037; Amino Acid Anal.: (Phe (1.00), Lys (1.01), Pro (1.06), Cha (1.94), Leu (1.09), Ala (0.86), Arg (1.04)
EXAMPLE 55
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2'S,3S )-3-Amino-2-oxo-1-pyrrolidine-{2'-(4'-methyl)}-pentanoyl}-DAlanyl-Arginyl-O
FAB.sup.+ MS: (M+H).sup.+ =985; Amino Acid Anal.: Phe (0.98), Lys (0.94), Asp (1.01), Cha (0.95), Ala (1.06), Arg (1.07)
EXAMPLE 56
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DProlyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1037; Amino Acid Anal.: Phe (0.99), Lys (0.99), Ala (0.93), Cha (1.94), Leu (1.09), Pro (0.83), Arg (1.07)
EXAMPLE 57
H-Phenylalanyl-Histidyl-Lysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1077
EXAMPLE 58
Ac-(4-NH.sub.2)Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropan oyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1112; Amino Acid Anal.: (4-NH.sub.2)Phe (0.75), Lys (1.02), Asp (0.98), Cha (1.90), Leu (1.09), Ala (0.99, Arg (1.03)
EXAMPLE 59
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-SCH.sub.2 CH.sub.3
N-alpha-Boc-Arginine is reacted with ethylmercaptan, according to the procedure described by Yamada, S.; Yokoyama, Y.; Shioiri, T. J. Org. Chem. 1974, 39, 3302. The ester obtained is treated with 4N-HCl/dioxane and coupled with the protected heptapeptide (cited in Example 49). Final deprotection is carried out by treatment with 4N-HCl/dioxane to give the desired product.
EXAMPLE 60
Ac-Phenylalanyl-Lysyl-Asparaginyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropan oyl}-Leucyl-DAlanyl-Tryptophyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1110
EXAMPLE 61
H-Phenylalanyl-Lysyl-6-Aminohexanoyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =900; Amino Acid Anal.: Phe (0.98), Lys (0.99), Cha (0.94), Leu (1.07), Ala (1.01), Arg (1.02)
EXAMPLE 62
H-(4-I)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S) -2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1137
EXAMPLE 63
H-Tyrosyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3 -cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1027; Amino Acid Anal.: Tyr (0.32), Lys (1.00), Ala (1.89), Cha (1.45), Leu (1.19), Arg (1.12)
EXAMPLE 64
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl)-{(2S)-2-Amino-3-cyclohexylpr opanoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-NHCH.sub.2 CH.sub.3
N-alpha-Boc-Arginine is coupled with ethylamine using mixed anhydride method conditions. Deprotection of the product with 4N-HCl/dioxane yields arginine ethylamide dihydrochloride which is coupled with the protected heptapeptide (cited in Example 49) using DCC/HOBT. The protecting groups are removed by treatment with 4N-HCl/dioxane to give the desired product.
EXAMPLE 65
H-Phenylalanyl-Arginyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)- 2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1083; Amino Acid Anal.: Phe (0.94), Arg (1.98), Asp (1.07), Cha (2.01), Leu (1.14), Ala (0.82)
EXAMPLE 66
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =973
EXAMPLE 67
H-(4-CH.sub.3)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl }-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: (4-Me)Phe (0.76), Lys (0.99), Ala (1.71), Cha (1.92), Leu (1.07), Arg (1.02)
EXAMPLE 68
H-(4-F)Phenylalanyl(R/S)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1029
EXAMPLE 69
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-NHCH.sub.2 C.sub.6 H.sub.5
This compound is prepared by the same method described in Example 64 with the exception that benzylamine is used instead of ethylamine.
EXAMPLE 70
H-(4-F)Phenylalanyl(R/S)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1029; Amino Acid Anal.: (4-F)Phe (0.96), Lys (1.03), Ala (1.94), Cha (1.96), Leu (1.07), Arg (1.00)
EXAMPLE 71
H-(3-F)Phenylalanyl(R/S)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1029; Amino Acid Anal.: (3-F)Phe (0.84), Lys (1.00), Ala (1.84), Cha (1.98), Leu (1.03), Arg (0.99)
EXAMPLE .eta.
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-NH(2-Pyridyl)methyl
This compound is synthesized by the same method described in Example 64 with the exception that (2-pyridyl)methylamine is used instead of ethylamine.
EXAMPLE 73
H-(3-F)Phenylalanyl(R/S)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl{- }(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1029; Amino Acid Anal.: (3-F)Phe (0.85), Lys (0.99), Ala (0.84), Cha (1.98), Leu (1.03), Arg (1.00)
EXAMPLE 74
H-(2-F)Phenylalanyl(R/S)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1029; Amino Acid Anal.: (2-F)Phe (1.01), Lys (1.00), Ala (1.95), Cha (2.02), Leu (1.08), Arg (1.04)
EXAMPLE 75
H-(2-F)Phenylalanyl(R/S)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1029; Amino Acid Anal.: (2-F)Phe (0.99), Lys (0.99), Ala (1.84), Cha (1.98), Leu (1.03), Arg (1.00)
EXAMPLE 76
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-NHNHC.sub.6 H.sub.5
The compound is prepared in analogy to Example 38.
EXAMPLE 77
H-Phenylalanyl-Lysyl-Alanyl-Leucyl-Leucyl-Leucyl-DAlanyl-Histidyl-OH
FAB.sup.+ MS: (M+H).sup.+ =912
EXAMPLE 78
H-(4-NO.sub.2)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl }-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1056 Amino Acid Anal.: (4-NO.sub.2)Phe (0.69), Lys (0.99), Ala (1.83), Cha (1.94), Leu (1.07), Arg (1.00)
EXAMPLE 79
H-Phenylalanyl-Lysyl-Phenylalanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S )-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087
EXAMPLE 80
Phenoxyacetyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =998
EXAMPLE 81
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-N(--CH.sub.2 C.sub.6 H.sub.5)NH.sub.2
The compound is prepared in analogy to Example 38.
EXAMPLE 82
H-Tryptophyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amin o-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1050
EXAMPLE 83
H-Phenylalanyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS (M+H).sup.+ =1077
EXAMPLE 84
H-{3-(2'-Naphthyl)alanyl}-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1061
EXAMPLE 85
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OCH.sub.2 C.sub.6 H.sub.5
N-alpha-Boc-Arginine is converted to its benzyl ester, according to the procedure described by Wang, S.-S.; Gisin, B. F.; Winter, D. P.; Makofske, R.; Kulesha, I. D.; Tzougraki, C. and Meienhofer, J. J. Org. Chem. 1977, 42, 1286. The compound obtained is treated with 4N-HCl/dioxane and coupled with the protected heptapeptide (cited in Example 45) using DCC/HOBT . The protecting groups are removed by treatment with 4N-HCl/dioxane to give the desired product.
EXAMPLE 86
H-{3-(1'-Naphthyl)alanyl}-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1061
EXAMPLE 87
H-(3-F)Phenylalanyl(R/S)-Lysyl-DAlanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -DAlanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =947
EXAMPLE 88
H-Phenylalanyl-Lysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl)-3-(Aminomethyl)be nzoyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =920
EXAMPLE 89
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-Dpipecolyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1051
EXAMPLE 90
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-NHOCH.sub.3
The compound is prepared in analogy to Example 38.
EXAMPLE 91
H-Phenylalanyl-Lysyl-Asparaginyl-Phenylalanyl-Phenylalanyl-Leucyl-DAlanyl-A rginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1042
EXAMPLE 92
H-Phenylalanyl-Lysyl-Alanyl-Phenylalanyl-Phenylalanyl-Leucyl-DAlanyl-Arginy l-OH
FAB.sup.+ MS: (M+H).sup.+ =999
EXAMPLE 93
H-Phenylalanyl-Lysyl-Phenylalanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S )-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Histidyl-OH
FAB.sup.+ MS (M+H).sup.+ =1068
EXAMPLE 94
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-4-pentenoyl}-Leucyl-Glycyl-Arginyl-OH
EXAMPLE 95
Ac-Histidyl-Lysyl-Asparaginyl-(2-CH.sub.3)Phenylalanyl(R/S)-(2-CH.sub.3)Phe nylalanyl(R/S)-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1102; Amino Acid Anal.: Asx (1.01), Leu (0.97), His (0.89), Ala (1.00), Lys (1.01), Arg (1.04)
EXAMPLE 96
Ac-Histidyl-Lysyl-Asparaginyl-(4-CH.sub.3)Phenylalanyl(R/S)-(4-CH.sub.3)Phe nylalanyl(R/S)-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1102
EXAMPLE 97
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{2-Amino-2 -methyl-propanoyl}-Leucyl-DAlanyl-Arginyl-OH
EXAMPLE 98
Ac-Arginyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-A mino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1105; Amino Acid Anal.: Asx (0.97), Ala (0.98), Leu (1.02), Cha (1.88), Lys (1.01), Arg (2.02)
EXAMPLE 99
Ac-Aspartyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DA lanyl-Arginyl-OH
The trifluoroacetic acid salt of Aspartyl(beta-Benzyl)-Lysyl(N-epsilon-Cbz)-{(2S)-2-Amino-3-cyclohexylpropa noyl}-{(2S)-2-Amino-cyclohexylpropanoyl}-Leucyl-D-Alanyl-Arginine(N-guanidi no-Tos)-OResin (0.56 g) was prepared according to the procedure described in Example 1. The peptide-resin obtained was washed with 10%-diisopropylethylamine (DIEA) in methylene chloride (3.times.15 mL, 45 seconds each) and methylene chloride (4.times.15 mL). 10%-DIEA in methylene chloride (15 mL) was introduced into the reaction vessel and acetic anhydride (0.47 mL, 5 mmole) was added. It was reacted at room temperature for 1 hour and repeated if neccesary (until Kaiser test was negative). The N-acetyl-peptide-resin was treated with HF and anisole to yield 127.3 mg of dried powder A portion of the powder (75 mg) was purified by HPLC, according to the procedure mentioned in Example 2 to yield 40.4 mg of pure product consistent with proposed structure.
FAB.sup.+ MS: (M+H).sup.+ =1064 Amino Acid Anal.: Asx (1.85), Ala (1.04), Leu (1.08), Cha (1.89), Lys (0.96), Arg (1.07)
EXAMPLE 100
H-{(2R)-2-Amino-3-cyclohexylpropanoyl}-DLysyl-DAspartyl-{(2R)-2-Amino-3-cyc lohexylpropanoyl}-{(2R)-2-Amino-3-cyclohexylpropanoyl}-DLeucyl-Alanyl-DArgi nyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1061
EXAMPLE 101
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{Aminocycl opropyl-1-carbonyl}-Leucyl-DAlanyl-Arginyl-OH
EXAMPLE 102
H-Phenylalanyl-Lysyl-Lysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1068
EXAMPLE 103
H-{3-(2'-Thienyl)alanyl(.+-.)}-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1084
EXAMPLE 104
H-Phenylalanyl-Lysyl-Alanyl-(4-I)Phenylalanyl-Alanyl-Leucyl-DAlanyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1049
EXAMPLE 105
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{Aminocycl ohexyl-1-carbonyl}-Leucyl-DAlanyl-Arginyl-OH
EXAMPLE 106
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-4-cyclohexylbutanoyl}-Alanyl-Leuc yl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =943
EXAMPLE 107
H-Phenylalanyl-Lysyl-Alanyl-(3-F)Phenylalanyl(R/S)-Alanyl-LeuCyl-DAlanyl-Ar ginyl-OH
FAB.sup.- MS: (M-H).sup.- =939
EXAMPLE 108
H-Phenylalanyl-Lysyl-Alanyl-(3-F)Phenylalanyl(R/S)-Alanyl-Leucyl-DAlanyl-Ar ginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =941
EXAMPLE 109
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-4-phenylbutanoyl}-Alanyl-Leucyl-D Alanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =937
EXAMPLE 110
Ac-{(1R/S)(2R/S)((Z)-1-Amino-2-phenylcyclopropyl)-1-carbonyl}-Lysyl-Alanyl- {(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-L eucyl-DAlanyl-Arginyl-OH
The C-terminal heptapeptide is prepared under standard solid phase peptide synthesis conditions. The epsilon nitrogen of lysine is protected as its Fmoc derivative which remains intact through the acidic cleavage of the heptapeptide from the resin. Racemic ((Z)-1-Acetamido-2-phenylcyclopropane)-1-carboxylic acid is prepared from Z-acetamidocinnamic acid according to the methodology given in, Schmidt, U.; Lieberknecht, A.; Wild, J. Synthesis 1988, 159-172, and the references cited therein. This amino acid is then coupled in solution phase to the heptapeptide by the mixed acid anhydride method, and the Fmoc group is removed with piperidine. Separation of the diastereomeric products by HPLC furnishes the final product.
EXAMPLE 111
H-Isoleucyl-Seryl-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1255
EXAMPLE 112
H-Phenylalanyl-Lysyl-Alanyl-{(2R/S)-2-Aminooctanoyl}-Alanyl-Leucyl-DAlanyl- Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =917
EXAMPLE 113
H-Phenylalanyl-Lysyl-Alanyl-{(2R/S)-2-Aminooctanoyl}-Alanyl-Leucyl-DAlanyl- Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =917
EXAMPLE 114
H-Phenylalanyl-Lysyl-Alanyl-{3-(2'-Thienyl)alanyl(R/S)}-Alanyl-Leucyl-DAlan yl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 115
Ac-{(Z)-2-Amino-3-phenyl-2-propenoyl}-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohex ylpropanoyl}-Alanyl-Leucyl-Glycyl-Arginyl-OH
The C-terminal heptapeptide is prepared using standard solid phase peptide synthesis techniques. The lysine is incorporated with the epsilon nitrogen protected with Fmoc which survives HF cleavage of the peptide from the resin and removal of the other protecting groups. Z-Acetamidocinnamic acid is coupled to the heptapeptide in solution phase employing the mixed acid anhydride method. The Fmoc group is subsequently removed with piperidine, and the crude peptide is purified by HPLC.
EXAMPLE 116
H-Alanyl-Asparaginyl-Isoleucyl-Seryl-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAla nyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1440
EXAMPLE 117
H-Phenylalanyl-Lysyl-Alanyl-Phenylseryl-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =939
EXAMPLE 118
H-Phenylalanyl-Lysyl-Leucyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leu-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1053
EXAMPLE 119
(N,N-Dimethyl)Alanyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cy clohexylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 120
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-(omega-N, omega'-N-diethyl)Arginyl-OH FAB.sup.+ MS: (M+H).sup.+ =1081; Amino Acid Anal.: Ala (1.91), Leu (1.09), Phe (0.96), Cha (1.98), Lys (0.96)
EXAMPLE 121
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-(omega-N-phenyl)Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087; Amino Acid Anal.: Ala (1.86), Leu (0.98), Phe (1.07), Cha (1.98), Lys (1.11)
EXAMPLE 122
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-(omega-N-methyl)Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Ala (1.90), Leu (1.25), Phe (0.95), Cha (2.25), Lys (1.08), Arg (1.08)
EXAMPLE 123
(N-Methyl)Phenylalanyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3- cyclohexylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 124
Ac-Histidyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-NHOH
The compound was prepared in analogy to Example 38.
FAB.sup.+ MS: (M+H).sup.+ =1101
EXAMPLE 125
Ac-Phenylalanyl-Lysyl-Glutamyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2 -Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
The synthesis, deprotection and cleavage of the resin-bound peptide was carried out as outlined in Examples 1 and 2 except for the acetylation of the N-terminus which occurred between the synthesis and deprotection/cleavage steps. The acetylation was carried out as described in "Solid Phase Peptide Synthesis" by John M. Stewart and Janis D. Young, Second Edition (1984), p. 73.
FAB.sup.+ MS: (M+H).sup.+ =1111
EXAMPLE 126
H-phenylalanyl-Lysyl-Glutamyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1069
EXAMPLE 127
(N-Benzyl)Glycyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cycloh exylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 128
H-Phenylalanyl-Ornithyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2 -Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =997
EXAMPLE 129
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Lysyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1026
EXAMPLE 130
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Glutamyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1027
EXAMPLE 131
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Threonyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =999
EXAMPLE 132
(N-Phenyl)Glycyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-L eucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 133
H-Leucyl-Arginyl-Alanyl-Asparaginyl-Isoleucyl-Seryl-Phenylalanyl-Lysyl-Aspa rtyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropano yl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1709
EXAMPLE 134
H-Phenylalanyl-Glutaminyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2 S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1055
EXAMPLE 135
H-Phenylalanyl-Alanyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2 -Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =998
EXAMPLE 136
Alpha-Hydrazinohistidyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-A lanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 137
2-Pyridylacetyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2 -Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1049
EXAMPLE 138
H-{(2S)-2-Amino-4-phenylbutanoyl}-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexyl propanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1091
EXAMPLE 139
(5-Dimethylamino-1-naphthalenesulfonyl)-Lysyl-Histidyl-{(2S)-2-Amino-3-cycl ohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginy l-OH
FAB.sup.+ MS: (M+H).sup.+ =1163
EXAMPLE 140
Methoxyacetyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexy lpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 141
(1,2,3,4-Tetrahydroisoquinolin-3-carbonyl(.+-.)}-Lysyl-Histidyl-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlan yl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1089
EXAMPLE 142
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-CyClohexylpropanoyl}-Leucyl-DPhenylalanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087
EXAMPLE 143
H-phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Glycyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS (M+H).sup.+ =955; Amino Acid Anal.: Phe (1.01), Lys (1.07), Ala (1.90), Cha (2.10), Arg (1.06), Gly (0.97)
EXAMPLE 144
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Alanyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =969; Amino Acid Anal.: Phe (1.03), Lys (1.01), Ala (2.86), Cha (2.11), Arg (1.10)
EXAMPLE 145
H-Phenylalanyl-{(2S)-2-Amino-5-ureidopentanoyl}-Alanyl-{(2S)-2-Amino-3-cycl ohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginy l-OH
FAB.sup.+ MS: (M+H).sup.+ =1040
EXAMPLE 146
Hydroxyacetyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexy lpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 147
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-2-cyclohexylpropanoyl}-Lysyl-Leuc yl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =986
EXAMPLE 148
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glutamyl-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =987
EXAMPLE 149
H-Phenylalanyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2'R/S, 3S)-3-Amino-2-oxo-1-azepine-2'-pentanoyl}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1021
EXAMPLE 150
H-Phenylalanyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2'R/S, 3S)-3-Amino-2-oxo-1-azepine-2'-pentanoyl}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1021
EXAMPLE 151
beta-Phenylethyl-oxy-acetyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Ami no-3-cyclohexylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 152
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-{(2R/S)-2-Amino-4,4,4-trifluorobutanoyl}- Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1079
EXAMPLE 153
H-Phenylalanyl-Lysyl-Alanyl-(3-{2'-Perhydronaphthyl)alanyl}-Alanyl-Leucyl-D Alanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =983
EXAMPLE 154
H-Phenylalanyl-Lysyl-Alanyl-{3-(2'-Naphthyl)alanyl}-Alanyl-Leucyl-DAlanyl-A rginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =973
EXAMPLE 155
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-{(2R/S)-2-Amino-4,4,4-trifluorobutanoyl}- Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1079
EXAMPLE 156
2-Methylthioacetyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cycl ohexylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 157
H-Phenylalanyl-Lysyl-Alanyl-{3-(1'-Naphthyl)alanyl}-Alanyl-Leucyl-DAlanyl-A rginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =973
EXAMPLE 158
H-Phenylalanyl-Lysyl-Alanyl-{3-(2'-(5'-tert-Butylthienyl))alanyl(R/S)}-Alan yl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =985
EXAMPLE 159
H-Phenylalanyl-Lysyl-Alanyl-{3-(2'-(5'-tert-Butylthienyl))alanyl(R/S)}-Alan yl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =985
EXAMPLE 160
H-Phenylalanyl-Lysyl-Alanyl-{3-(2'-Thienyl)alanyl(R/S)}-Alanyl-Leucyl-DAlan yl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 161
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2'RS,3S) -3-Amino-2-oxo-1-pyrrolidine-{2'-(4'-methyl)}-pentanoyl}-DProlyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =967
EXAMPLE 162
4-Phenylbutyryl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Le ucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 163
H-Phenylalanyl-Lysyl-Alanyl-{3-(1'-Perhydronaphthyl)alanyl}-Alanyl-Leucyl-D Alanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =983
EXAMPLE 164
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Threonyl-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =959
EXAMPLE 165
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Phe (0.99), Lys (1.04), Ala (1.92), Cha (1.00), Leu (1.07), Arg (1.02), Gly (0.97)
EXAMPLE 166
H-Penylalanyl-Lysyl-Alanyl-Lysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucy l-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =986
EXAMPLE 167
Phenylacetyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucy l-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 168
H-Phenylalanyl-Lysyl-Alanyl-Glutamyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =987
EXAMPLE 169
H-{(2S)-2-Amino-4-phenylbutanoyl}-Lysyl-Alanyl-{(2S)-2-Amino-4-phenylbutano yl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =951
EXAMPLE 170
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-4-phenylbutanoyl}-Alanyl-Alanyl-D Alanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =985
EXAMPLE 171
Pyrazylcarbonyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2 -Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1036
EXAMPLE 172
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-(N -Hydroxy)Asparaginyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 173
3-Cyclopentylpropanoyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1054
EXAMPLE 174
(3-Benzoyl)benzoyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S )-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1138
EXAMPLE 175
{1,2,3,4-Tetrahydronaphthyl-carbonyl(.+-.)}-Lysyl-Histidyl-{(2S)-2-Amino-3- cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Ar ginyl-OH
FAB.sup.+ MS: (M+Na).sup.+ =1110
EXAMPLE 176
(N-Methyl)phenylalanyl-Lysyl-Glycyl-.psi.{CH.sub.2 CO--NH}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlan yl-Arginyl-OH
EXAMPLE 177
H-Phenylalanyl-Lysyl-Nipecotyl(.+-.)-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{ (2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1051
EXAMPLE 178
4-Phenylbutanoyl-Lysyl-Histidyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)- 2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1076
EXAMPLE 179
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-4-phenylbutanoyl}-{Aminocyclohexy l-3-carbonyl(R/S)}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =878
EXAMPLE 180
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-4-phenylbutanoyl}-{Aminocyclohexy l-3-carbonyl(R/S)}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =878
EXAMPLE 181
(N-Methyl)Phenylalanyl-Lysyl-Glycyl-.psi.{S(O).sub.2 --NH}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl -Arginyl-OH
EXAMPLE 182
H-Phenylalanyl-Lysysl-Alanyl-Threonyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =959
EXAMPLE 183
H-Phenylalanyl-Lysyl-Alanyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leu cyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929; Amino Acid Anal.: Phe (1.05), Lys (0.97), Ala (2.69), Cha (0.93), Leu (1.20), Arg (1.03)
EXAMPLE 184
H-Phenylalanyl-Lysyl-Glycyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAl anyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Phe (1.10), Lys (1.04), Ala (1.93), Cha (1.01), Leu (1.23), Arg (1.08), Gly (0.95)
EXAMPLE 185
H-Phenylalanyl-Lysyl-DAlanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-A mino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011
EXAMPLE 186
(N-Methyl)Phenylalany-1-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-A lanyl-Leucyl-.psi.{C.intg.C}-Glycyl-Arginyl-OH
The Boc-Leu-Gly-OH alkyne isotere is prepared in analogy to the procedure described in the literature ('van Marsenille, M.; Gysen, C.; Tourwe, D.; van Vinst, G. Bull. Soc. Chim. Belg. 1986, 108, 825.) and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 187
H-Alanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3- cyclohexylpropanoyl}-leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =935; Amino Acid Anal.: Lys (0.99), Ala (2.48), Cha (1.74), Leu (1.03), Arg (0.98)
EXAMPLE 188
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-Alanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011
EXAMPLE 189
H-Phenylalanyl-Lysyl-Glycyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =997; Amino Acid Anal.: Phe (0.99), Lys (1.01), Ala (0.73), Cha (1.80), Leu (1.06), Arg (0.99), Gly (0.95).
EXAMPLE 190
H-Glycyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3- cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =921; Amino Acid Anal.: Phe (0.97), Lys (1.03), Ala (1.70), Cha (1.85), Leu (1.09), Arg (1.00)
EXAMPLE 191
(N-Methyl)Phenylalanyl-Lysyl-Glycyl-.psi.{C(.dbd.S)--NH}-{(2S)-2-Amino-3-cy clohexylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
The Boc-Glycyl-.psi.{C(.dbd.S)--NH}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-OH dipeptide is prepared in analogy to the procedure described in the literature (Maziak, L.; Lajoie, G.; Belleau, B. J. Am. Chem. Soc. 1986, 108, 182.) and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Kalusner, and M. A. Ondetti (1976).
EXAMPLE 192
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =997; Amino Acid Anal.: Phe (0.97), Lys (1.00), Ala (0.98), Cha (1.82), Leu (1.07), Arg (0.98), Gly (0.80)
EXAMPLE 193
H-Penicillaminyl*-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Cystein yl*-Leucyl-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =943
EXAMPLE 194
H-DPenicillaminyl*-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Cystei nyl*-Leucyl-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =943
EXAMPLE 195
Benzoyl-Penicillaminyl*-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-C ysteinyl*-Leucyl-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =1047
EXAMPLE 196
Benzoyl-Penicillaminyl*-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-C ysteinyl*-Leucyl-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =1047
EXAMPLE 197
H-Phenylalnyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-DLysyl-Leuc yl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =986
EXAMPLE 198
(N-Methyl)phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{CH.sub.2 --O}-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{CH.sub.2 --O}-Glycyl-OH dipeptide is prepared in analogy to the procedure described in the literature (Rubini, E.; Gilson, C.; Selinger, Z.; Chorev, M. Tetrahedron 1986, 42, 6039.) and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 199
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-DAlanyl-Le ucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 200
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-(4-NH.sub.2)Phenylalanyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011
EXAMPLE 201
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2R)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011
EXAMPLE 202
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-DAlanyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =969
EXAMPLE 203
H-Phenylalanyl-Lysyl-Alanyl-Phenylalanyl-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =923
EXAMPLE 204
H-{2-Aminooctanoyl(.+-.)}-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclo hexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1196
EXAMPLE 205
H-Phenylalanyl-Lysyl-Alanyl-{(R/S)-Perhydroindole-2-carbonyl}-Alanyl-Leucyl -DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =927
EXAMPLE 206
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{CH.sub.2 --S}-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{CH.sub.2 --S}-Glycyl-OH dipeptide is prepared in analogy to the procedure described in the literature (Spatola, A.; Anwer, M.; Rockwell, A.; Gierasch, L. J. Am. Chem. Soc. 1986, 108, 825.) and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 207
H-Phenylalanyl-Lysyl-Alanyl-{(R/S)-Perhydroindole-2-carbonyl}-Alanyl-Leucyl -DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =927
EXAMPLE 208
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 209
H-Phenylalanyl-Lysyl-Alanyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-Alanyl-Leucy l-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =951
EXAMPLE 210
H-Phenylalanyl-Lysyl-Alanyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-Alanyl-Leucy l-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =951
EXAMPLE 211
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl)-Leucyl-DAlanyl-Arginyl-Glycyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1068
EXAMPLE 212
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{C(.dbd.O)--O}-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{C(.dbd.O)--O}-Glycyl-OH dipeptide is prepared in analogy to the procedure described in the literature (Roy, J.; Gazis, D.; Shakman, R.; Schwartz, I. L. Int. J. Peptide Protein Res. 1982, 20, 35.) and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 213
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl)-Leucyl-DAlanyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1068
EXAMPLE 214
H-phenylalanyl-Lysyl-Alanyl-{(trans-3-propyl)Prolyl(R/S)}-Alanyl-Leucyl-DAl anyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =915
EXAMPLE 215
H-Phenylalanyl-Lysyl-Alanyl-{(trans-3-propyl)Prolyl(R/S)}-Alanyl-Leucyl-DAl anyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =915
EXAMPLE 216
H-Phenylalanyl-Lysyl-(3,5-di-I)Tyrosyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1273
EXAMPLE 217
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-DTryptophy l-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1044
EXAMPLE 218
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Tryptophyl -Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1044
EXAMPLE 219
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{C(.dbd.O)--S}-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{C(.dbd.O)--S}-Glycyl-OH dipeptide is prepared by standard coupling of Boc-leucine mixed anhydride with thiolacetic acid and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 220
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-DPhenylala nyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1005; Amino Acid Anal.: Phe (2.00), Lys (1.04), Ala (1.86), Cha (1.26), Leu (1.07), Arg (1.04)
EXAMPLE 221
H-Phenylalanyl-Lysyl-Alanyl-DTryptophyl-{(2S)-2-Amino-3-cyclohexylpropanoyl }-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1044
EXAMPLE 222
H-Phenylalanyl-Alanyl-DLysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Le ucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 223
H-Phenylalanyl-Lysyl-(3-I)Tyrosyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alan yl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M-H).sup.- =1145
EXAMPLE 224
H-Phenylalanyl-Lysyl-Alanyl-Alanyl-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =847
EXAMPLE 225
Iodoacetyl-Phenylalanyl-Lysyl-Lysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1154
EXAMPLE 226
H-Phenylalanyl-Lysyl-Alanyl-(4-NO.sub.2)Phenylalanyl-Alanyl-Leucyl-DAlanyl- Argiyl-OH
FAB.sup.+ MS: (M+H).sup.+ =968
EXAMPLE 227
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{CH.sub.2 C(.dbd.O)--O}-Glycyl-Arginyl-OH
The Boc-Leu-.psi.{CH.sub.2 C(.dbd.O)}--OH is prepared by Arndt-Eistert synthesis as described in the literature (Wakamiya, T.; Uratani, H.; Teshima, T.; Shiba, T. Bull. Chem. Soc. Jpn. 1975, 48, 2401.) Boc-Leucyl-.psi.{CH.sub.2 C(.dbd.O)--O}-Glycyl-OH is prepared in analogy to Example 212. The peptide is prepared by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 228
H-Phenylalanyl-Lysyl-Alanyl-(4-NH.sub.2)Phenylalanyl-Alanyl-Leucyl-DAlanyl- Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =938
EXAMPLE 229
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Ala (1.01), Leu (0.99), Phe (0.96), Cha (197), Lys (1.04), Arg (1.02)
EXAMPLE 230
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-(N-Methyl)Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Ala (1.94), Phe (1.00), Cha (2.00), Lys (1.03), Arg (1.04)
EXAMPLE 231
H-Phenylalanyl-Lysyl-Cysteinyl*-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)- 2-Amino-3-cyclohexylpropanoyl}-Penicillaminyl*-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =1059
EXAMPLE 232
H-Phenylalanyl-Lysyl-Cysteinyl*-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)- 2-Amino-3-cyclohexylpropanoyl}-DPenicillaminyl*-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =1059; Amino Acid Anal.: Ala (0.85), Phe (1.00), Cha (1.98), Lys (0.99), Arg (1.03)
EXAMPLE 233
H-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohe xylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =1017; Amino Acid Anal.: Ala (1.88), Leu (1.07), Cha (2.78), Lys (1.02), Arg (1.04)
EXAMPLE 234
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{CH.sub.2 C(.dbd.O)--S}-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{CH.sub.2 C(.dbd.O)--S}-Glycyl-OH dipeptide is prepared by standard coupling of Boc-Leu-.psi.{CH.sub.2 C(.dbd.O))}--OH, which is prepared as described in Example 227, mixed anhydride with thiolacetic acid and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 235
H-Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025
EXAMPLE 236
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ (M+H).sup.+ =1096
EXAMPLE 237
Phenoxyacetyl-Lysyl-Lysyl**-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl**
FAB.sup.+ MS: (M+H).sup.+ =1037
EXAMPLE 238
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(3,4-dehy dro)Prolyl(R/S)}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =953
EXAMPLE 239
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(3,4-dehy dro)Prolyl(R/S)}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =953
EXAMPLE 240
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{CH.dbd.CH}-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.CH.dbd.CH}-Glycyl-OH ethylenic isostere is prepared in analogy to the procedure described in the literature (Spaltenstein, A.; Carpino, P.; Miyake, F.; Hopkins, P. Tetrahedron Lett. 986, 27, 2095.) and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 241
H-Phenylalanyl-Lysyl-{(3,4-dehydro)Prolyl(R/S)}-{(2S)-2-Amino-3-cyclohexylp ropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =953
EXAMPLE 242
H-Phenylalanyl-Lysyl-{(3,4-dehydro)Prolyl(R/S)}- (2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ (M+H).sup.+ =953
EXAMPLE 243
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-DArginyl-Glycyl-OH
FAB.sup.+ MS: (M+H).sup.+ =915
EXAMPLE 244
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1140
EXAMPLE 245
H-Phenylalanyl-Lysyl-Alanyl-Tryptophyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1044
EXAMPLE 246
H-Phenylalanyl-Lysyl-Alanyl-{(2R)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011
EXAMPLE 247
H-Phenylalanyl-Lysyl-Alanyl-DAlanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Le ucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 248
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{CH.sub.2 --CH.sub.2 }-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{CH.sub.2 --CH.sub.2 }-Glycyl-OH isostere is prepared by hydrogenating Boc-Leucyl-.psi.{CH.dbd.CH}-Glycyl-OH, which is prepared as described in Example 240, with palladium-carbon and incorporated into the peptide in analogy to the synthesis of Example 2.
EXAMPLE 249
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-DTr yptophyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =988
EXAMPLE 250
H-Histidyl-Lysyl-Phenylalanyl-Tyrosyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087
EXAMPLE 251
H-Phenylalanyl-Lysyl-Glycyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =901; Amino Acid Anal.: Phe (1.00), Lys (1.17), Cha (1.07), Leu (1.08), Ala (0.94), Arg (1.07), Gly (1.91)
EXAMPLE 252
H-(4-NO.sub.2)Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropano yl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1185
EXAMPLE 253
H-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclo hexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginy l-OH
FAB.sup.+ MS: (M+H).sup.+ =1146
EXAMPLE 254
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3- cyclohexylpropanoyl}-Alanyl-Leucyl-.psi.{C(.dbd.O)--CH.sub.2 }-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{C(.dbd.O)--CH.sub.2)-Glycyl-OH isostere is prepared in analogy to the procedure described in the literature (McMurray, J.; Dyckes, D. J. Org. Chem. 1985, 50, 1112.) and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 255
H-(3-NO.sub.2)Tyrosyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{ (2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1201
EXAMPLE 256
H-Tryptophyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1179
EXAMPLE 257
H-{3-(2'-Thienyl)alanyl(R/S)}-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylprop anoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1146
EXAMPLE 258
H-{3-(2'-Thienyl)alanyl(R/S)}-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylprop anoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1146
EXAMPLE 259
H-(4-CH.sub.3)Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropano yl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1154
EXAMPLE 260
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{CH(--OH)--CH.sub.2 })-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{C(.dbd.O)--CH.sub.2)-Glycyl-OH isostere is prepared in analogy to the procedure described in the literature (McMurray, J.; Dyckes, D. J. Org. Chem. 1985, 50, 1112.), reduced to Boc-Leucyl-.psi.{CH(--OH)--CH.sub.2 }-Glycyl-OH with sodium borohydride in methanol and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 261
H-{3-(2'-(5'-tert-Butylthienyl))alanyl(.+-.)}-Lysyl-Aspartyl-{(2S)-2-Amino- 3-cyclohexylpropanoyl)}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginy l-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1202
EXAMPLE 262
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =901; Amino Acid Anal.: Phe (1.07), Lys (0.97), Ala (1.10), Cha (1.05), Gly (1.64), Leu (1.06), Arg (1.15)
EXAMPLE 263
H-Histidyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-(4-NH.sub.2)Ph enylalanyl-Leucyl-DAlanyl-(4-NH.sub.2)Phenylalanyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1016
EXAMPLE 264
H-(4-NH.sub.2)Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropano yl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1155
EXAMPLE 265
H-(3-NH.sub.2)Tyrosyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{ (2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1171
EXAMPLE 266
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Phenylalan yl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1005; Amino Acid Anal.: Phe (1.98), Lys (1.00), Ala (1.90), Cha (1.07), Leu (1.07), Arg (1.04)
EXAMPLE 267
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{C(.dbd.CH.sub.2)--CH.sub.2 }-Glycyl-Arginyl-OH
The Boc-Leucyl-.psi.{C(.dbd.CH.sub.2)--CH.sub.2 }-Glycyl-OH isostere is prepared by condensing methylenetriphenylphosphorane and Boc-Leucyl-.psi.{CO--CH.sub.2 }-Glycyl-OH which is prepared as described in the literature (McMurray, J.; Dyckes, D. J. Org. Chem. 1985, 50, 1112.), and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 268
H-Phenylalanyl-Lysyl-Alanyl-Phenylalanyl-{(2S)-2-Amino-3-cyclohexylpropanoy l}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1005; Amino Acid Anal.: Phe (1.98), Lys (1.00), Ala (1.89), Cha (1.10), Leu (1.08), Arg (1.05)
EXAMPLE 269
H-(1-CH.sub.3)Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1144
EXAMPLE 270
H-(3-CH.sub.3)Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H) .sup.+ =1144
EXAMPLE 271
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glutamin yl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H) .sup.+ =1016
EXAMPLE 272
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glutaminyl- Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1062 ; Amino Acid Anal.: His (0.95), Lys (1.00), Asp (0.97), Cha (0.9), Gln (1.03), Leu (1.05), Ala (0.97), Arg (1.03)
EXAMPLE 273
H-Phenylalanyl-Lysyl-}(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Alanyl-Leu cyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929; Amino Acid Anal.: Phe (1.00), Lys (1.01), Cha (0.96), Ala (2.92), Leu (1.05), Arg (1.02)
EXAMPLE 274
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Methylamino-3-cyclohexylpropanoyl}-{(2S )-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Ala (1.63), Leu (1.04), Phe (0.96), Cha (0.95), Lys (0.97), Arg (1.03)
EXAMPLE 275
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-Cyclohexylpropanoyl}-Al anyl-Leucyl-.psi.{C(.dbd.O)--N(OMe)}-Glycyl-Arginyl-OH
The Boc-N(OMe)-Glycyl-OH is prepared as described in the literature (Ottenheijm, H.; Herscheid, J. Chem. Rev. 1986, 86, 697.), and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 276
Benzoyl-Penicillaminyl*-Lysyl-Alanyl-}(2S)-2-Amino-3-cyclohexylpropanoyl}-{ (2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DCysteinyl*-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =1129; Amino Acid Anal.: Ala (0.98), Leu (1.01), Cha (1.90), Lys (0.99), Arg (1.03)
EXAMPLE 277
H-DPenicillaminyl*-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)- 2-Amino-3-cyclohexylpropanoyl}-Leucyl-DCysteinyl*-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025
EXAMPLE 278
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Me thylamino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Ala (1.89), Leu (1.04), Phe (0.96), Cha (0.99), Lys (1.00), Arg (1.08)
EXAMPLE 279
Benzoyl-DPenicillaminyl*-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl)- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DCysteinyl*-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1129; Amino Acid Anal.: Ala (0.84), Leu (0.88), Cha (2.01), Lys (1.01), Arg (1.04)
EXAMPLE 280
H-Phenylalanyl-Lysyl-Glycyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =887 Amino Acid Anal Phe (1.02), Lys (1.02), Cha (1.03), Leu (1.09), Arg (1.05), Gly (2.82)
EXAMPLE 281
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Gl y-.psi.{PO(OH)--NH}-Leucyl-Gly-Arginyl-OH
The Cbz-Gly-.psi.{PO(OH)-NH}-Leucyl-Gly-OH is prepared as described in the literature (Bartlett, P.; Marlowe, C. Biochemistry 1987, 26, 8554.), and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 282
H-Phenylalanyl-Lysyl-Alanyl-DPhenylalanyl-Glycyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =909; Amino Acid Anal.: Phe (1.93), Lys (0.99), Ala (2.00), Gly (0.98), Leu (1.08), Arg (1.03)
EXAMPLE 283
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Phe nylalanyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =949; Amino Acid Anal.: Phe (2.14), Lys (.97), Ala (1.77), Cha (1.04), Gly (0.99), Arg (1.13)
EXAMPLE 284
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-DPh enylalanyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =949; Amino Acid Anal.: Phe (1.96), Lys (1.00), Ala (2.01), Cha (1.02), Gly (1.00), Arg (1.03)
EXAMPLE 285
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Try ptophyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =988; Amino Acid Anal.: Phe (1.02), Lys (1.04), Ala (1.84), Cha (1.04), Arg (1.11), Gly (0.82), Trp (0.75)
EXAMPLE 286
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-Alanyl-DArginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011
EXAMPLE 287
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3cyclohexylpropanoyl}-Gly -.psi.{PO(OMe)--NH}-Leucyl-Gly-Arginyl-OH
The Cbz-Gly-.psi.{PO(OMe)--NH}-Leucyl-Gly-OH is prepared in analogy to the procedure described in the literature (Bartlett, P.; Marlowe, C. Biochemistry 1987, 26, 8554.), and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 288
H-Phenylalanyl-Lysyl-{(2R)-2-Amino-3-cyclohexylpropanoyl)-Alanyl-Alanyl-Leu cyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 289
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Phe (0.91), Lys (1.06), Asp (0.94), Met (0.85), Gln (1.02), Leu (1.07), Gly (0.99), Arg (1.02)
EXAMPLE 290
Ac-Histidyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glutaminyl- Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1048
EXAMPLE 291
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-D(4-NO.sub.2)Phenylalanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1050; Acid Anal.: Phe (0.67), Lys (0.66), Ala (1.59), Cha (0.93), Leu (1.00), D(4-NO.sub.2)Phe (0.92), Arg (1.00)
EXAMPLE 292
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1033; Amino Acid Anal Phe (0.94), Lys (1.00), hhPhe (0.82), Cha (0.93), Ala (2.00), Leu (1.04), Arg (1.01)
EXAMPLE 293
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1033
EXAMPLE 294
H-Phenylalanyl-Alanyl-Lysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929
EXAMPLE 295
H-Phenylalanyl-Lysyl-Alanyl-Alanyl-Leucyl-Alanyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =847
EXAMPLE 296
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =943; Amino Acid Anal.: Ala (1.94), Leu (1.06), Phe (0.96), Cha (0.94), Lys (0.96), Arg (1.02)
EXAMPLE 297
Formyl-.psi.{NH--CO}-DPhenylalanyl-.psi.{NH--CO}-DLysyl-.psi.{NH--NMeDAla-A rginyl-OH
The Formyl-.psi.{NH--CO}-DPhenylalanyl-.psi.{NH--CO}-DLysyl-.psi.{NH--CO}Glycy l-OH fragment is prepared by classical solution methods (exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y.S. Klausner, and M. A. Ondetti 1976. ) and is incorperated into the peptide in analogy to Example 2.
EXAMPLE 298
H-Phenylalanyl-Lysyl-Penicillaminyl*-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{ (2S)-2-Amino-3-cyclohexylpropanyl}-Leucyl-DCysteinyl*-Arginyl-OH
The compound was prepared in analogy to Example 334.
FAB.sup.+ MS: (M+H).sup.+ =1101
EXAMPLE 299
H-Phenylalanyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S) -2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-NCH.sub.3 NH.sub.2
The compound was prepared in analogy to Example 38.
FAB.sup.+ MS: (M+H).sup.+ =1082; Amino Acid Anal.: Asx (1.02), Ala (0.94), Leu (1.05), Phe (0.98), Cha (1.96), Lys (0.97), Arg (1.06)
EXAMPLE 300
H-Phenylalanyl-Lysyl-Asparaginyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S) -2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-NHNH.sub.2
The compound was prepared in analogy to Example 38.
FAB.sup.+ MS: (M+H).sup.+ =1068; Amino Acid Anal. Asx (0.98), Ala (0.99), Leu (1.08), Phe (100), Cha (1.97), Lys (1.03), Arg (1.04)
EXAMPLE 301
(N-Methyl){(2S)-2-Amino-3-cyclohexylpropanoyl)-Lysyl-Alanyl-{(2S)-2-Amino-3 -cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-A rginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1031; Amino Acid Anal.: Ala (1.87), Leu (1.06), Cha (1.96), Lys (1.01), Arg (1.06)
EXAMPLE 302
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-(2 S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Ala (1.87), MePhe (0.87), Leu (1.06), Cha (1.92), Lys (0.98), Arg (1.04)
EXAMPLE 303
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Alanyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =955; Amino Acid Anal.: Phe (0.99), Lys (1.03), Ala (1.98), Cha (2.14), Gly (0.91), Arg (1.09)
EXAMPLE 304
H-Phenylalanyl-Lysyl-Glycyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =983; Amino Acid Anal.: Phe (1.00), Lys (1.06), Cha (2.18), Gly (1.79), Leu (1.07), Arg (1.08)
EXAMPLE 305
Ac-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Le ucyl-DAlanyl-Tyrosyl-OH
FAB.sup.+ MS: (M+H).sup.+ =978
EXAMPLE 306
H-Phenylalanyl-Lysyl-Tyrosyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Le ucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1021
EXAMPLE 307
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Gl y-.psi.{PO(NHMe)--NH}-Leucyl-Gly-Arginyl-OH
The Cbz-Gly-.psi.{PO(OH)--NH}-Leucyl-Gly-OtBu is prepared in analogy to the procedure described in the literature (Bartlett, P.; Marlowe, C. Biochemistry 1987, 26, 8554.), coupled with methyl amine and deprotected to give Cbz-Gly-.psi.{PO(NHMe)--NH}-Leucyl-Gly-OH. Cbz-Gly-.psi.}PO(NHMe)--NH}-Leucyl-Gly-OH is incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 308
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-DLeucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011
EXAMPLE 309
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Agmatine
The peptide was synthesized following the procedure described in Example 1 with the exception that the N-terminal protecting group was not removed at the end of the synthesis. Cleavage of the peptide from the resin was accomplished by transesterification with methanol as described in "Solid Phase Peptide Synthesis" by John M. Stewart and Janis D. Young, Second Edition (1984), p. 91. The methyl ester was hydrolyzed with sodium hydroxide and the peptide then coupled with agmatine sulfate using a DCC mediated coupling procedure. The protecting groups were removed by treatment with liquid HF/anisole.
FAB.sup.+ MS: (M+H).sup.+ =967
EXAMPLE 310
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Sarcosyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =969; Amino Acid Anal.: Phe (1.01), Lys (1.04), Ala (1.87), Cha (1.94), Arg (1.08), Sar (1.10)
EXAMPLE 311
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Sarcosyl-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929; Amino Acid Anal: Phe (0.97), Lys (1.00), Ala (1.98), Cha (1.02), Leu (1.04), Arg (1.01), Sar (1.13)
EXAMPLE 312
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-Sarcosyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011; Amino Acid Anal.: Phe (0.97), Lys (1.00), Ala (0.96), Cha (1.93), Leu (1.04), Arg (1.03), Sar (0.93)
EXAMPLE 313
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Gl y-.psi.{PO(NMe.sub.2)--NH}-Leucyl-Gly-Arginyl-OH
The Cbz-Gly-.psi.{PO(OH)--NH}-Leucyl-Gly-OtBu is prepared in analogy to the procedure described in the literature (Bartlett, P.; Marlowe, C. Biochemistry 1987, 26, 8554.), coupled with dimethyl amine and deprotected to give Cbz-Gly-.psi.{PO(NMe.sub.2)--NH}-Leucyl-Gly-OH. Cbz-Gly-.psi.{PO(NMe.sub.2)-NH)-Leucyl-Gly-OH is incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 314
H-Phenylalanyl-Lysyl-Sarcosyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1011; Amino Acid Anal.: Phe (0.99), Lys (1.02), Leu (1.07), Ala (0.86), Cha (2.12), Arg (1.05), Sar (1.13)
EXAMPLE 315
H-Phenylalanyl-Lysyl-Alanyl-Sarcosyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-L eucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =929; Amino Acid Anal.: Phe (0.99), Lys (1.04), Ala (1.83), Cha (1.06), Leu (1.08), Arg (1.06), Sar (1.11)
EXAMPLE 316
H-Phenylalanyl-Lysyl-DPhenylalanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Gly cyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =991; Amino Acid Anal.: Phe (2.00), Lys (1.03), Cha (1.08), Gly (0.95), Leu (1.10), Ala (0.86), Arg (1.07)
EXAMPLE 317
H-phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-DPhenylalanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =991; Amino Acid Anal.: Phe (1.95), Lys (0.99), Ala (1.02), Cha (1.04), Gly (0.92), Leu (1.07), Arg (1.05)
EXAMPLE 318
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Gl y-.psi.{PO(NH.sub.2)--NH}-Leucyl-Gly-Arginyl-OH
The Cbz-Gly-.psi.{PO(OH)--NH}-Leucyl-Gly-OtBu is prepared in analogy to the procedure described in the literature (Bartlett, P.; Marlowe, C. Biochemistry 1987, 26, 8554.), coupled with ammonia and deprotected to give Cbz-Gly-.psi.}PO(NH.sub.2)--NH}-Leucyl-Gly-OH. Cbz-Gly-.psi.{PO(NH.sub.2)--NH}-Leucyl-Gly-OH is incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 319
H-Phenylalanyl-Lysyl-Phenylalanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glyc yl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =991; Amino Acid Anal.: Phe (1.95), Lys (0.97), Gly (0.92), Leu (1.07), Ala (0.93), Arg (1.00)
EXAMPLE 320
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-Tryptophyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1030
EXAMPLE 321
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-Phenylalanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =991; Amino Acid Anal.: Phe (1.94), Lys (0.99), Ala (1.02), Gly (0.96), Leu (1.07), Arg (1.03)
EXAMPLE 322
Ac-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cy clohexylpropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1075
EXAMPLE 323
Ac-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cy clohexylpropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1075
EXAMPLE 324
Formyl-.psi.{NH--CO}-DPhenylalanyl-.psi.}NH--CO}-DLysyl-.psi.{NH--CO--NH}Gl ycyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-NMeDAla-Arginyl-OH
The H-DLysyl-DPhenalanyl-NH.sub.2 fragment is prepared by classical solution methods (exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti 1976. ) and is coupled with methyl isocyanoacetate to give Formyl-.psi.{NH--CO}-DPhenylalanyl-.psi.{NH--CO}-DLysyl-.psi.{NH--CO--NH}G lycyl-OMe. It is then hydrolyzed to the corresponding carboxylic acid and incorporated into the peptide by classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodanszky, Y. S. Klausner, and M. A. Ondetti (1976).
EXAMPLE 325
H-Valyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-DAl anyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =881; Amino Acid Anal.: Ala (2.93), Val (1.03), Leu (1.02), Cha (0.97), Lys (1.01), Arg (1.01)
EXAMPLE 326
H-Phenylalanyl-Sarcosyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2 -Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =954; Amino Acid Anal : Phe (1.00), Ala (1.91), Cha (1.98), Leu (1.07), Arg (1.05), Sar (0.63)
EXAMPLE 327
H-Sarcosyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino- 3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =935; Amino Acid Anal.: Lys (1.12), Ala (1.48), Cha (2.16), Leu (1.17), Arg (1.23), Sar (0.63)
EXAMPLE 328
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Alanyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1019
EXAMPLE 329
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Alanyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1019
EXAMPLE 330
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Glycyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1005
EXAMPLE 331
Hydrocinnamoyl-(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohex ylpropanoyl}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
EXAMPLE 332
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Glycyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1005
EXAMPLE 333
(N-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpro panoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =957
EXAMPLE 334
N-Benzoyl-DPenicillaminyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DCysteinyl-Arginine Cyclic disulfide
N-Benzoyl-DPenicillaminyl(S-4-methylbenzyl)-Lysyl(N-epsilon-Cbz)-Alanyl-{(2 S)-2-Amino-3-cyclohexylpropanoyl){-(2S)-2-Amino-3-cyclohexylpropanoly}-Leuc yl-DCycteinyl(S-4-methylbenzyl)-Arginyl(N-guanidino-Tos)-OResin (0.6 g) was prepared by the method of Example 1 and was treated with HF and anisole as illustrated in Example 2. After extraction of the crude peptide by treatment with 2.times.25 mL of degassed 20% aqueous acetic acid, it was then diluted to 1,500 mL with degassed, distilled water. The pH of the solution was adjusted to 8.0 by the addition of concentrated ammonium hydroxide. Potassium ferricyanide aqueous solution (0.01N) was added dropwise to the stirred solution until a yellow color appeared. The resultant solution was stirred for an additional 30 minutes at room temperature, and the pH was adjusted to 5.0 with glacial acetic acid. Packed Bio-Rad anion exchange resin AGX-4 (10 mL, Cl form) was added, stirred for 30 minutes and filtered. The filtrate was applied to a column containing 150 g XAD-16 molecular adsorbent resin. The sample was desalted by first washing the column with 1 L of distilled water and then eluting from the column with 1 L of 50% aqueous ethanol. The combined ethanol fractions were concentrated to approximately 100 mL in vacuo and lyophilized to a dried powder. The crude peptide was then purified by HPLC as described in Example 2. The compound obtained (12 mg) gave NMR and mass spectra consistent with the proposed structure.
FAB.sup.+ MS: (M+H).sup.+ =1129
EXAMPLE 335
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-DPh enylalanyl-DPhenylalanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1025; Amino Acid Anal.: Phe (2.92), Lys (1.01), Ala (1.01), Gly (1.00), Arg (1.06), Cha (1.04)
EXAMPLE 336
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-L eucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1058
EXAMPLE 337
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Glycyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1019
EXAMPLE 338
H-Tryptophyl(N-formyl)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{( 2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1078
EXAMPLE 339
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}{(2S)-2-Amino-3-cycl ohexylpropanoyl}-Glycyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1019
EXAMPLE 340
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Alanyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1118
EXAMPLE 341
H-Phenylalanyl-Lysyl-{(2R/S)-2-Amino-5-phenylpentanoyl}-{(2S)-2-Amino-3-cyc lohexylpropanoyl}-Alanyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1118
EXAMPLE 342
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-Arginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1140
EXAMPLE 343
H-phenylalanyl-Lysyl-Aspartyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-L eucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1058
EXAMPLE 344
H-Phenylalanyl-Lysyl-Aspartyl-Alanyl-Alanyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =976
EXAMPLE 345
H-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Lysyl-Aspartyl-Methionyl-Glutaminyl- Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1000
EXAMPLE 346
H-Phenylalanyl-Lysyl-Alanyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =950
EXAMPLE 347
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-DTryptophyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1030
EXAMPLE 348
H-Phenylalanyl-(S-2-Aminoethyl)Cysteinyl-Alanyl-{(2S)-2-Amino-3-cyclohexylp ropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
The synthesis, deprotection and cleavage of the resinbound peptide was carried out as oulined in Examples 1 and 2. The S-(2-aminoethyl)-L-cysteine residue was protected as the N-alpha Boc, N-epsilon Cbz derivative prior to incorporation into the peptide.
FAB.sup.+ MS: (M+H).sup.+ =1029
EXAMPLE 349
H-Phenylalanyl-Lysyl-Alanyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leu cyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1014
EXAMPLE 350
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}(2S)-2-Am ino-3-cyclohexylpropanoyl}-Leucyl-DHistidyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1121
EXAMPLE 351
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DAspartyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1099
EXAMPLE 352
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1014
EXAMPLE 353
H-Phenylalanyl-Lysyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Alanyl-Leu cyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1014
EXAMPLE 354
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-DAlanyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =1008
EXAMPLE 355
H-Phenylalanyl-Lysyl-Alanyl-(N-Methyl)Alanyl-Sarcosyl-Leucyl-DAlanyl-Arginy l-OH
FAB.sup.+ MS: (M+H).sup.+ =861
EXAMPLE 356
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-(N-Methyl) Alanyl-Sarcosyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =901
EXAMPLE 357
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Am ino-3-cyclohexylpropanoyl}-(N-Methyl)Alanyl-Sarcosyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =983
EXAMPLE 358
(N-(2-phenyl)ethyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylprop anoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1033
EXAMPLE 359
H-Phenylalanyl-Lysyl-Alanyl-Alanyl-Alanyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =932
EXAMPLE 360
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glutamin yl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1030
EXAMPLE 361
Ac-Phenylalanyl-Lysyl-Aspartyl-Leucyl-Glutaminyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1018
EXAMPLE 362
Ac-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-DAlanyl-Arginyl- OH
FAB.sup.+ MS: (M+H).sup.+ =1050
EXAMPLE 363
Ac-Phenylalanyl-Lysyl-Aspartyl-Leucyl-Glutaminyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1032
EXAMPLE 364
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Prolyl-L eucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1084
EXAMPLE 365
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Arginyl- Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1143
EXAMPLE 366
H-Phenylalanyl-Lysyl-Aspartyl-[(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-Arginyl-DArginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1140
EXAMPLE 367
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-DArginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1140
EXAMPLE 368
H-(1-CH.sub.3)Histidyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Ar ginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =998
EXAMPLE 369
H-(3-CH.sub.3)Histidyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Ar ginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =998
EXAMPLE 370
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glutamin yl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1115
EXAMPLE 371
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-Cyclohexylpropanoyl}-Glycyl-Leu cyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1000
EXAMPLE 372
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-DArginyl-Arginyl- OH
FAB.sup.+ MS: (M+H).sup.+ =1093
EXAMPLE 373
H-Phenylalanyl-Lysyl-Aspartyl-[(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2'R/S, 3S)-3-Amino-2-oxo-1-pyrrolidine-}2'-(4'-methyl)}-pentanoyl}-DArginyl-Arginy l-OH
FAB.sup.+ MS: (M+H).sup.+ =1070
EXAMPLE 374
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2'R/S, 3S)-3-Amino-2-oxo-1-pyrrolidine-}2'-(4'-methyl)}-pentanoyl}-DArginyl-Arginy l-OH
FAB.sup.+ MS: (M+H).sup.+ =1070
EXAMPLE 375
H-Phenylalanyl-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoy l}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-DLeucyl-DArginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1087
EXAMPLE 376
H-{3-(1'-Naphthyl)alanyl}-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl -Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1043
EXAMPLE 377
H-{3-(2'-Naphthyl)alanyl}-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl -Arginyl-OH
FAB.sup.+ MS (M+H).sup.+ =1043
EXAMPLE 378
H-{3-(2'-Thienyl)alanyl(R/S)}-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Gl ycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1000
EXAMPLE 379
H-{3-(2'-Thienyl)alanyl(R/S)}-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Gl ycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1000
EXAMPLE 380
H-{(2S)-2-Amino-4-phenylbutanoyl)-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpr opanoyl}-Alanyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1028
EXAMPLE 381
H-{(2R/S)-2-Amino-5-phenylpentanoyl}-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexy lpropanoyl}-Alanyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1042
EXAMPLE 382
H-{(2R/S)-2-Amino-5-phenylpentanoyl}-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexy lpropanoyl}-Alanyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1042
EXAMPLE 383
4-Phenylbutanoyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-L eucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1013
EXAMPLE 384
H-Phenylalanyl-.psi.{CH.sub.2 --NH}-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-DAla nyl-Arginyl-OH
The compound was prepared in analogy to Example 413.
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Ala (2.97), Leu (1.02), Cha (0.89), Arg (1.01)
EXAMPLE 385
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =957; Amino Acid Anal.: Ala (2.04), Leu (1.05), MePhe (0.87), Cha (0.98), Lys (1.03), Arg (1.01)
EXAMPLE 386
(N-alpha-(2-phenyl)ethyl)Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =900
EXAMPLE 387
H-Phenylalanyl-Lysyl-Aspartyl-DMethionyl-Glutaminyl-Leucyl-DArginyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1093; Amino Acid Anal.: Asp (0.93), Glx (1.06), Met (0.68), Leu (1.07), Phe (0.97), Lys (0.92), Arg (2.06)
EXAMPLE 388
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-DGlutaminyl-Leucyl-DArginyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1093; Amino Acid Anal. : Asp (0.95), Glx (1.07), Met (0.61), Leu (1.05), Phe (0.98), Lys (0.91), Arg (2.04)
EXAMPLE 389
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-DArginyl-DArginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1093; Amino Acid Anal. Asp (0.97), Glx (1.06), Met (0.68), Leu (1.05), Phe (0.97), Lys (0.92), Arg (2.03)
EXAMPLE 390
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-DLeucyl-DArginyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1093; Amino Acid Anal.: Asp (0.98), Glx (1.05), Met (0.57), Leu (1.06), Phe (0.97), Lys (0.92), Arg (2.02) EXAMPLE 391
Phenoxyacetyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leuc yl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1001
EXAMPLE 392
Phenoxypropanoyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-L eucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1015
EXAMPLE 393
H-Phenylalanyl-Lysyl-Glycyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{ (2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1197
EXAMPLE 394
3-phenylpropanoyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl- Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =999
EXAMPLE 395
H-Phenylalanyl-Lysyl-3-Aminopropanoyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- {(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1096
EXAMPLE 396
H-Phenylalanyl-(N-Methyl)Alanyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =968
EXAMPLE 397
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-DLysyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1112
EXAMPLE 398
H-phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Isoleucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1055
EXAMPLE 399
H-Phenylalanyl-Lysyl-Aspartyl-Alanyl-Alanyl-Isoleucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =891
EXAMPLE 400
H-Phenylalanyl-Lysyl-DAspartyl-Methionyl-Glutaminyl-Leucyl-DArginyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1093; Amino Acid Anal.: Asp (0.97), Glx (1.04), Met (0.59), Leu (1.06), Phe (0.94), Lys (0.89), Arg (2.09)
EXAMPLE 401
H-DPhenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-DArginyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =1093; Amino Acid Anal.: Asp (0.95), Glx (1.05), Met (0.59), Leu (1.05), Phe (0.97), Lys (0.93), Arg (2.07)
EXAMPLE 402
(N-Ethyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Ala nyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =971; Amino Acid Anal.: Ala (2.02), Leu (1.03), Cha (0.97), Lys (1.01), Arg (0.99)
EXAMPLE 403
(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Al anyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-NHNH.sub.2
The compound was prepared in analogy to Example 38.
FAB.sup.+ MS: (M+H).sup.+ =971; Amino Acid Anal.: Ala (2.01), MePhe (0.85), Leu (1.02), Cha (0.93), Lys (0.98), Arg (0.99)
EXAMPLE 404
tert-Butyloxycarbonyl-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylp ropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1029
EXAMPLE 405
(N-iPr)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alany l-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =985; Amino Acid Anal.: Ala (2.07), Leu (0.96), Cha (0.97), Lys (0.99), Arg (0.98)
EXAMPLE 406
H-D(N-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl} -Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =957; Amino Acid Anal.: Ala (1.97), Leu (1.04), Cha (0.93), Lys (0.97), Arg (1.02)
EXAMPLE 407
H-Phenylalanyl-Lysyl-Aspartyl(NHNH.sub.2)-{(2S)-2-Amino-3-cyclohexylpropano yl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-(N-Methyl)DAlanyl-Arginyl-N HNH.sub.2
The compound was prepared in analogy to Example 38.
FAB.sup.+ MS: (M+H).sup.+ =1083
EXAMPLE 408
H-Phenylalanyl-Lysyl-Aspartyl(NCH.sub.3 NH.sub.2)-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylp ropanoyl}-Leucyl-(N-Methyl)DAlanyl-Arginyl-NCH.sub.3 NH.sub.2
The compound was prepared in analogy to Example 38.
FAB.sup.+ MS: (M+H).sup.+ =1111
EXAMPLE 409
H-phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-Cyclohexylpropanoyl}-Alanyl-.ps i.{CH.sub.2 --NH}-Leucyl-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 413.
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Ala (1.97), Phe (0.99), Cha (1.79), Lys (1.02), Arg (1.01)
EXAMPLE 410
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-.psi.{CH.sub.2 --NH)-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 413.
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Ala (2.02), Phe (0.97), Cha (0.94), Lys (1.01), Arg (0.82)
EXAMPLE 411
H-Phenylalanyl-Lysyl-Alanyl-.psi.{CH.sub.2 --NH}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-DAlanyl-Arginyl-O H
The compound was prepared in analogy to Example 413.
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Ala (2.06), Leu (1.05), Phe (0.94), Lys (0.99), Arg (0.95)
EXAMPLE 412
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-.psi.{CH.s ub.2 --NH}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
The compound was prepared in analogy to Example 413.
FAB.sup.+ MS: (M+H).sup.+ =915;Amino Acid Anal.: Ala (2.00), Leu (1.02), Phe (0.97), Lys (1.02), Arg (1.02)
EXAMPLE 413
H-Phenylalanyl-Lysyl-.psi.{CH.sub.2 --NH}-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leucyl-DAlanyl-Ar ginyl-OH
Commercially available N-alpha-Boc-Lysine(N-epsilon-Cbz) was converted to its N,O-dimethylhydroxamate, which was reduced with lithium aluminum hydride to yield N-alpha-Boc-N-epsilon-Cbz-Lysinal, according to the literature: Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815. The peptide chain was then elongated by the method described in Example 1, except that after Boc-Alanine was coupled, the sequence was stopped at agenda A-step 2. N-alpha-Boc-N-epsilon-Cbz-Lysinal (235 mg, 3.5 equivalent mole) in 10 mL of DMF containing 0.1% glacial acetic acid was added, followed by sodium cyanoborohydride (404 mg, 10 equivalent mole). The reaction was allowed to proceed at room temperature for 1 hour. After the peptide resin obtained was washed with DMF (3.times.10 mL) and methylene chloride (3.times.10 mL), the next synthetic protocol (Example 1, Agenda A step 2) was initiated. The peptide-resin was then treated as described in Example 2 to yield 27.8 mg of pure product consistent with proposed structure.
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Ala (1.99), Leu (1.01), Phe (0.94), Cha (0.93), Arg (1.06)
Other amino aldehydes (Boc-Phenylalanal, Boc-(2S)-2-amino-3-cyclohexylpropanal, Boc-Alanal, Boc-Leucinal and Boc-D-Alanal were prepared by literature methods: Anhoury, M. L.; Arickx, M.; Crooy, P.; De Neys, R.; Eliaers, J. J. Chem. Soc. Perkin 1 1974, 191; Hamada, Y.; Shioiri, T. Chem. Pharm. Bull. 1982, 30, 1921.
EXAMPLE 414
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-DArginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Asp (0.95), Glx (1.08), Gly (0.77), Met (0.56), Leu (1.04), Phe (0.97), Lys (0.94), Arg (1.03)
EXAMPLE 415
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-DLeucyl-Glycyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Asp (0.96), Glx (0.93), Gly (0.67), Met (0.54), Leu (1.06), Phe (0.97), Lys (0.88), Arg (1.05)
EXAMPLE 416
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-DGlutaminyl-Leucyl-Glycyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Asp (0.97), Glx (1.08), Gly (0.67), Met (0.61), Leu (1.04), Phe (0.98), Lys (0.88), Arg (1.05)
EXAMPLE 417
H-Phenylalanyl-Lysyl-Aspartyl-DMethionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Asp (0.47), Glx (0.32), Gly (0.68), Met (0.64), Leu (1.00), Phe (0.27), Lys (0.30), Arg (1.00)
EXAMPLE 418
H-Phenylalanyl-Lysyl-DAspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Asp (0.46), Glx (0.28), Gly (0.68), Met (0.59), Leu (1.00), Phe (0.24), Lys (0.29), Arg (1.00)
EXAMPLE 419
H-Phenylalanyl-DLysyl-Aspartyl-Methionyl-Glutaminyl-LeucylGlycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Asp (0.47), Glx (0.31), Gly (0.84), Met (0.53), Leu (1.04), Phe (0.22), Lys (0.26), Arg (0.96)
EXAMPLE 420
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-3-Aminop ropanoyl-Leucyl-DArginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1058
EXAMPLE 421
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-DAlanyl-.psi.{CH.sub.2 --NH}-Arginyl-OH
The compound was prepared in analogy to Example 413.
FAB.sup.+ MS: (M+H).sup.+ =915; Amino Acid Anal.: Ala (1.80), Leu (1.02), Phe (1.02), Cha (1.00), Lys (0.97)
EXAMPLE 422
(N-(3-Phenyl)propyl)Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alany l-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =914
EXAMPLE 423
(N,N-di-(3-Phenyl)propyl)Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}- Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1032;Amino Acid Anal.: Ala (2.10), Leu (1.06), Cha (0.97), Lys (0.93), Arg (1.04)
EXAMPLE 424
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Arginyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1022; Amino Acid Anal.: Asp (0.62), Gly (0.99), Met (0.49), Leu (1.13), Phe (0.30), Lys (0.35), Arg (1.88)
EXAMPLE 425
H-Phenylalanyl-Lysyl-Arginyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1035; Amino Acid Anal.: Glx (0.38), Gly(0.83), Met (0.91), Leu (1.13), Phe (0.27), Lys (0.27), Arg (1.96)
EXAMPLE 426
H-Phenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Lysyl-OH
FAB.sup.+ MS: (M+H).sup.+ =966- Amino Acid Anal.: Asp(0.70), Glx (0.32), Gly (0.94), Met (0.66), Leu (1.19), Phe (0.35), Lys (1.89)
EXAMPLE 427
H-Phenylalanyl-Ornithyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =980; Amino Acid Anal.: Asp (0.49), Glx (0.32), Gly (0.71), Met (0.65), Leu (1.00), Phe (0.33), Orn (0.25), Arg (1.00)
EXAMPLE 428
H-DPhenylalanyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =994; Amino Acid Anal.: Asp (0.45), Glx (0.30), Gly (0.70), Met (0.68), Leu (1.00), Phe (0.30), Lys (0.43), Arg (1.00)
EXAMPLE 429
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-Glycyl-Arginyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1197
EXAMPLE 430
H-Phenylalanyl-Lysyl-Aspartyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2- Amino-3-cyclohexylpropanoyl}-Leucyl-Glycyl-Arginyl-DArginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1197
EXAMPLE 431
3-Phenylpropanoyl-Lysyl-Aspartyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl -OH
FAB.sup.+ MS: (M+H).sup.+ =979
EXAMPLE 432
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Arginyl-Le ucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1014; Amino Acid Anal.: Ala (1.86), Leu (1.04), Phe (1.00), Cha (0.96), Lys (0.99), Arg (1.97)
EXAMPLE 433
(N-Allyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Ala nyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =983; Amino Acid Anal.: Ala (1.98), Leu (1.04), Cha (0.94), Lys (0.96), Arg (1.02)
EXAMPLE 434
(N,N-di-Methyl)Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoy l}-Alanyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =971; Amino Acid Anal.: Ala (2.01), Leu (1.06), Cha (0.88), Lys (0.91), Arg (1.03)
EXAMPLE 435
Pyrazylcarbonyl-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropano yl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1035
EXAMPLE 436
Benzoyl-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alan yl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1033
EXAMPLE 437
2-Pyridylacetyl-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropano yl}-Alanyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1048
EXAMPLE 438
Ac-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Le ucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =971
EXAMPLE 439
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-(N-Bn)Glycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1005
EXAMPLE 440
{(3R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-Lysyl-Alanyl-{(2S)-2-Amin o-3-cyclohexylpropanoyl}-Glycyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =927; Amino Acid Anal.: Gly (0.90), Lys (1.01), Ala (1.78), Cha (0.98), Leu (1.00), Arg (1.02)
EXAMPLE 441
{(3R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-Lysyl-Alanyl-{(2S)-2-Amin o-3-cyclohexylpropanoyl}-Glycyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =927; Amino Acid Anal.: Gly (0.92), Lys (1.02), Ala (1.90), Cha (0.99), Leu (1.07), Arg (1.04)
EXAMPLE 442
H-Phenylalanyl-Lysyl-{(3R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-{(2S )-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1003
EXAMPLE 443
H-Phenylalanyl-Lysyl-{(3R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-{(2S )-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1003; Amino Acid Anal.: Phe (0.97), Lys (0.94), Ala (0.80), Gly (1.00), Leu (1.06), Arg (1.04)
EXAMPLE 444
H-Phenylalanyl-Lysyl-Alanyl-{(3R/S)}-1,2,3,4-Tetrahydroisoquinolin-3-carbon yl}-Glycyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =921; Amino Acid Anal.: Phe (0.96), Lys (0.97), Ala (1.82), Gly (0.96), Leu (1.05), Arg (1.03)
EXAMPLE 445
H-Phenylalanyl-Lysyl-Alanyl-{(3R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbony l}-Glycyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =921; Amino Acid Anal.: Phe (1.01), Lys (1.00), Ala (1.99), Gly (0.93), Leu (1.13), Arg (1.09)
EXAMPLE 446
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(3R/S)-1, 2,3,4-Tetrahydroisoquinolin-3-carbonyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1017; Amino Acid Anal.: Phe (0.99), Lys (0.96), Ala (1.69), Cha (0.99), Leu (1.06), Arg (1.00)
EXAMPLE 447
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(3R/S)-1, 2,3,4-Tetrahydroisoquinolin-3-carbonyl}-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1017; Amino Acid Anal.: Phe (1.01), Lys (1.02), Ala (1.79), Cha (0.99), Leu (1.10), Arg (1.08)
EXAMPLE 448
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-{(3 R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =961; Amino Acid Anal.: Phe (0.99), Lys (1.04), Ala (1.94), Gly (1.03), Leu (1.07), Arg (1.08)
EXAMPLE 449
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-{(3 R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =961; Amino Acid Anal.: Phe (1.00), Lys (1.03), Ala (2.01), Gly (0.94), Leu (1.07), Arg (1.02)
EXAMPLE 450
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glyeyl-Leu cyl-{(3R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1003; Amino Acid Anal.: Phe (0.90), Lys (0.91), Ala (1.02), Gly (0.98), Leu (1.02), Arg (1.06)
EXAMPLE 451
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycyl-Leu cyl-{(3R/S)-1,2,3,4-Tetrahydroisoquinolin-3-carbonyl}-Arginyl-OH
EXAMPLE 452
FAB.sup.+ MS: (M+H).sup.+ =1003
(N,N-di-Allyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexy lpropanoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1023; Amino Acid Anal.: Lys (0.91), Cha (0.98), Gly (0.99), Leu (1.05), Arg (0.99)
EXAMPLE 453
(N-Allyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylprop anoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =983; Amino Acid Anal.: Lys (0.93), Cha (0.90), Gly (0.91), Leu (1.05), Arg (1.02)
EXAMPLE 454
2-Indolylcarbonyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoy l}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =939; Amino Acid Anal.: Lys (0.86), Cha (0.97), Gly (1.01), Leu (1.03), Arg (0.96)
EXAMPLE 455
(N,N-di-Methyl)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohex ylpropanoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =971
EXAMPLE 456
Ac-(Z-dehydro)Phenylalanyl-Lysyl-(N-Methyl)Alanyl-{(2S)-2-Amino-3-cyclohexy lpropanoyl}-Glycyl-Leucyl-(N-Methyl)DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =983; Amino Acid Anal.: Lys (1.02), Gly (1.01), Cha (0.94), Leu (1.01), Arg (0.97)
EXAMPLE 457
Pivaloyl-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Ala nyl-Leucyl-DAlanyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1013
EXAMPLE 458
H-Phenylalanyl-Arginyl-Arginyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arginyl-O H
FAB.sup.+ MS: (M+H).sup.+ =1063; Amino Acid Anal.: Glx (0.31), Gly (0.84), Met (0.82), Leu (1.11), Phe (0.33), Arg (2.23)
EXAMPLE 459
H-Phenylalanyl-Lysyl-Arginyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Alanyl-OH
FAB.sup.+ MS: (M+H).sup.+ =950; Amino Acid Anal.: Glx (0.35), Gly (1.02), Ala (1.45), Met (0.97), Leu (1.31), Phe (0.26), Lys (0.30), Arg (1.00)
EXAMPLE 460
(N-Methyl)Phenylalanyl-Lysyl-Arginyl-Methionyl-Glutaminyl-Leucyl-Glycyl-Arg inyl-OH
FAB.sup.+ MS: (M+H).sup.+ =1049; Amino Acid Anal.: Glx (0.38), Gly (0.79), Met (0.91), Leu (0.92), Lys (0.14), Arg (1.67)
EXAMPLE 461
H-Phenylalanyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Alanyl-Leu cyl-Azaglycyl-Arginyl-OH
FAB.sup.+ MS: (M+H).sup.+ =917.
This peptide was prepared using methodology similar to that described in: Dutta, A. S.; Giles, M. B.; Williams, J C. J. Chem. Soc., Perkin Trans. 1 1986, 1655-64; Dutta, A. S.; Giles, M. B.; Gormley, J. J.; Williams, J. C.; Kusner, E. J. J. Chem. Soc., Perkin Trans. 1 1987, 111-120.
EXAMPLE 462
H-Phenylglycinyl-Lysyl-Alanyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Glycinyl -Leucyl-DAlanyl-Arginyl-OH
EXAMPLE 463
H-Phenylalanyl-Lysyl-Cysteinyl-{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2 -Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
The protected peptide resin: H-Phenylalanyl-Lysyl(N-epsilon-Cbz)-Cysteinyl(S-4-methylbenzyl) -{(2S)-2-Amino-3-cyclohexylpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl} -Leucyl-DAlanyl-Arginyl(N-guanidino-Tos)-Merrifield resin is prepared as described in Example 1. The peptide is cleaved from the resin as described in Example 2 with the following precautions: the peptide is extracted with degassed 20% aqueous acetic acid following cleavage with HF; and HPLC purification is accomplished using helium saturated solvents.
EXAMPLE 464
H-Phenylalanyl-Lysyl-(S-Benzyl)Cysteinyl-{(2S)-2-Amino-3-cyclohexylpropanoy l}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
The octapeptide prepared in Example 463 is dissolved in methanol saturated with ammonia to make a 0.03M solution under a nitrogen atmosphere, and the resultant solution is chilled to 0.degree. C. Benzyl bromide (1.3 equivalents) is introduced neat, and the reaction mixture is stirred for 1 hour at 0.degree. C. The entire reaction mixture is poured into water followed by trifluoroacetic acid addition to obtain a pH of 2. The product is subsequently isolated by HPLC using solvents saturated with helium.
EXAMPLE 465
2-Acetamidoacryloyl-Phenylalanyl-Arginyl-Aspartyl-{(2S)-2-Amino-3-cyclohexy lpropanoyl}-{(2S)-2-Amino-3-cyclohexylpropanoyl}-Leucyl-DAlanyl-Arginyl-OH
Excess 2-acetamido acrylic acid isobutyl mixed anhydride in tetrahydrofuran, prepared from 2-acetamido acrylic acid and isobutyl chloroformate by the standard method, is added into a stirred 0.degree. C. solution of the peptide prepared in Example 65 in 0.1N aqueous sodium bicarbonate containing sufficient acetonitrile to produce a homogenous solution. After stirring for 6 hours at 0.degree. C., the reaction mixture is brought to pH 2, and the peptide is purified by reverse phase HPLC followed by lyophilization.
The foregoing examples are merely illustrative of the invention and are not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which is defined in the appended claims.
Claims
We claim:
1. A C5a anaphylotoxin activity modulating compound of the formula: or a pharmaceutically acceptable salt thereof wherein the groups A through T have the values: A is R.sub.1 -R.sub.2 -R.sub.3 ; B is selected from the group consisting of R.sub.4 -R.sub.5 -R.sub.6, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; D is selected from the group consisting of R.sub.7 -R.sub.8 -R.sub.9, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; E is selected from the group consisting of R.sub.10 -R.sub.11 -R.sub.12, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; G is selected from the group consisting of R.sub.13 -R.sub.14 -R.sub.15, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; J is selected from the group consisting of R.sub.16 -R.sub.17 -R.sub.18, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; L is selected from the group consisting of R.sub.19 -R.sub.20 -R.sub.21, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; M is selected from the group consisting of R.sub.22 -R.sub.23 -R.sub.24, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; Q is selected from the group consisting of R.sub.25 -R.sub.26 -R.sub.27, R.sub.31, R.sub.32, R.sub.35 and R.sub.37 ; T is R.sub.28 -R.sub.29 -R.sub.30 ; or B and D, taken together, optionally represent a group selected from the group consisting of R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ; D and E, taken together, optionally represent a group selected from the group consisting of R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ; E and G, taken together, optionally represent a group selected from the group consisting of R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ; G and J, taken together, optionally represent a group selected from the group consisting of R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ; J and L, taken together, optionally represent a group selected from the group consisting of R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ; L and M, taken together, optionally represent a group selected from the group consisting of R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43 ; M and Q, taken together, optionally represent a group selected from the group consisting of R.sub.33, R.sub.34, R.sub.38, R.sub.39, R.sub.40, R.sub.41, R.sub.42, and R.sub.43, and one or more of the groups R.sub.5 -R.sub.6 -R.sub.7, R.sub.8 -R.sub.9 -R.sub.10, R.sub.11 -R.sub.12 -R.sub.13, R.sub.14 -R.sub.15 -R.sub.16, R.sub.17 -R.sub.18 -R.sub.19, R.sub.20 -R.sub.21 -R.sub.22, R.sub.23 -R.sub.24 -R.sub.25, or R.sub.26 -R.sub.27 -R.sub.28, independently may optionally represent R.sub.36 ; wherein (a) R.sub.1 is selected from the group consisting of amino,(lower alkyl)amino, dialkylamino, (arylalkyl)amino, hydroxy, alkoxy, arloxy, arylalkoxy, acetamido, thioalkoxy, halogen, aryl, lower alkyl, arylalkyl, (heterocyclic)alkyl, heterocyclic, arylamino, and hydrogen; (b) R.sub.2 is selected from the group consisting of >CR.sub.99 R.sub.100, >C.dbd.CR.sub.95 R.sub.96, existing in either the Z- or E-configuration, oxygen, amino, and alkylamino, with the proviso that when R.sub.2 is oxygen, amino or alkylamino, R.sub.1 is aryl, lower alkyl, arylalkyl or (heterocyclic)alkyl; (c) R.sub.3 is selected from the group consisting of >C.dbd.O,>CH.sub.2, >C.dbd.S, >SO.sub.2, with the proviso that when R.sub.3 is >CH.sub.2 or >SO.sub.2 then R.sub.2 cannot be oxygen, amino or alkylamino; (d) R.sub.4 is selected from the group consisting of >CH.sub.2,>O,>S, and >NR.sub.101 where R.sub.101 is hydrogen, lower alkyl, arylalkyl, alkenyl, hydroxy or alkoxy, with the proviso that when R.sub.4 is >O or >S then R.sub.1, R.sub.2 and R.sub.3 taken together represent a group selected from the group consisting of lower alkyl, arylalkyl, aryl or hydrogen; (e) R.sub.5 is selected from the group consisting of >CR.sub.201 R.sub.202, >NR.sub.203, >C.dbd.CR.sub.205 R.sub.206, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR27## (f) R.sub.6, R.sub.9, R.sub.12, R.sub.15, R.sub.18, R.sub.21, and R.sub.24 are independently selected from the group consisting of >C.dbd.O, >CH.sub.2, --CH.sub.2 C(O)--, --NHC(O), >C.dbd.S, >SO.sub.2, and >P(O)X where X is selected from the group consisting of hydroxy, alkoxy, amino, alkylamino and ialkylamino; (g) R.sub.7, R.sub.10, R.sub.13, R.sub.16, R.sub.19, R.sub.22, R.sub.25 are independently selected from the group consisting of >CH.sub.2 and >NR.sub.50 where R.sub.50 is selected from the group consisting of hydrogen, lower alkyl, arylalkyl, aryl, hydroxy and alkoxy; (h) R.sub.8 is selected from the group consisting of >CR.sub.210 R.sub.211, >NR.sub.213, >C.dbd.CR.sub.215 R.sub.216, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR28## (i) R.sub.11 is selected from the group consisting of >CR.sub.220 R.sub.221, >NR.sub.223, >C.dbd.CR.sub.225 R.sub.226, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR29## (j) R.sub.14 is selected from the group consisting of >CR.sub.230 R.sub.231, >NR.sub.233, >C.dbd.CR.sub.235 R.sub.236, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR30## (k) R.sub.17 is selected from the group consisting of >CR.sub.301 R.sub.302, >NR.sub.303, >C.dbd.CR.sub.305 R.sub.306, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR31## (l) R.sub.20 is selected from the group consisting of >CR.sub.310 R.sub.311, >NR.sub.313, >C.dbd.CR.sub.315 R.sub.316, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR32## (m) R.sub.23 is selected from the group consisting of >CR.sub.320 R.sub.321, >NR.sub.323, >C.dbd.CR.sub.325 R.sub.326, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formula ##STR33## (n) R.sub.26 is selected from the group consisting of >CR.sub.330 R.sub.331, >C.dbd.CR.sub.335 R.sub.336, existing in either the Z- or E-configuration, and substituted cyclopropyl of the formual ##STR34## (o) R.sub.27 is selected from the group consisting of >C.dbd.O, >CH.sub.2, --CH.sub.2 C(O)--, >C.dbd.S, >SO.sub.2, and >P(O)X wherein X is selected from hydroxy, alkoxy, amino, alkylamino and dialkylamino; (p) R.sub.28 is selected from the group consisting of >O, >S, >CH.sub.2, and >NR.sub.109 where R.sub.109 is selected from hydrogen, lower alkyl, (heterocyclic)alkyl, and arylalkyl, with the proviso that when R.sub.27 is >SO.sub.2 or >P(O)X, then R.sub.28 is >O or >NR.sub.109 ; (q) R.sub.29 is selected from the group consisting of hydrogen, lower alkyl, arylalkyl, and >NR.sub.110 where R.sub.110 is selected from hydrogen, lower alkyl, aryl, and arylalkyl, with the provisos that (i) when R.sub.28 is >O, or >S then R.sub.29 is lower alkyl or arylalkyl, and (ii) when R.sub.29 is hydrogen, lower alkyl, or arylalkyl then R.sub.30 is absent; (r) R.sub.30 is selected from the group consisting of hydrogen, aryl, lower alkyl, and arylalkyl; (s) R.sub.31 is ##STR35## where m and n are integers independently selected from 0, 1 and 2; (t) R.sub.32 is ##STR36## where p and q are integers independently selected from 0, 1 and 2; (u) R.sub.33 is ##STR37## where t and v are integers independently selected from 0, 1, 2 and 3; (v) R.sub.34 is ##STR38## where r and s are integers independently selected from 0, 1, 2 and 3; (w) R.sub.35 is ##STR39## where f is and integer of 0 to 3, X is selected from the group consisting of >C.dbd.O and --CH.sub.2 -- and R is selected from the group consisting of hydrogen and lower alkyl, with the provisos that (i) when f is 0,X is at C-2 and R is at C-3 or C-4; (ii) when f is 1, X is at C-2 and R is at C-3, C-4 or C-5 and C-3,4 are saturated or unsaturated; (iii) when f is 2, X is at C-2, C-3 or C-4 and R is at C-2, C-3, C-4, C-5 or C-6 when the position is unoccupied by X and C-3,4 or C-4,5 are saturated or unsaturated; and (iv) when f is 3, X is at C-2, C-3 or C-4 and R is at C-2, C-3, C-4, C-5, C-6 or C-7 when the position is unoccupied by X and C-3,4 or C-4,5 or C-5,6 are saturated or unsaturated; (x) R.sub.36 is ##STR40## where g is an integer of from 0 to 3; (y) R.sub.37 is ##STR41## wherein h is 0 or 1 and j is 0 or 1 with the proviso that either h or j must be 1; (z) R.sub.38 is ##STR42## (aa) R.sub.39 is ##STR43## (ab) R.sub.40 is ##STR44## (ac) R.sub.41 is ##STR45## (ad) R.sub.42 is ##STR46## (ae) R.sub.43 is ##STR47## where k is an integer of from zero to two; (af) R.sub.1 is R.sub.2, taken together, optionally represent a group selected from the group consisting of aryl, heterocyclic, and hydrogen; (ag) R.sub.6 and R.sub.7 ; R.sub.9 and R.sub.10 ; R.sub.12 and R.sub.13 ; R.sub.15 and R.sub.16 ; R.sub.18 and R.sub.19 ; R.sub.21 and R.sub.22 ; and R.sub.24 and R.sub.25 ; each pair taken together, optionally and independently represent a group selected from the group consisting of >CH.sub.2, --(CH.sub.2).sub.3 --, --CH.dbd.CH--, --C.intg.C--, --C(.dbd.CH.sub.2)CH.sub.2 --, --CH(OH)CH.sub.2 --, --C(O)O--, --C(O)S--, --CH.sub.2 C(O)O--, --CH.sub.2 C(O)S--, --CH.sub.2 O--, --CH.sub.2 S--, and --NHC(O)--, with the provisos that (i) when R.sub.5 is >NR.sub.203 or >C.dbd.CR.sub.205 R.sub.206, R.sub.6 and R.sub.7, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (ii) when R.sub.8 is >NR.sub.213 or >C.dbd.CR.sub.215 R.sub.216, R.sub.9 and R.sub.10, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (iii) when R.sub.11 is >NR.sub.223 or >C.dbd.CR.sub.225 R.sub.226, R.sub.12 and R.sub.13, taken together represent --C(O)NH-- or --C(O)NCH.sub.3 13 ; (iv) when R.sub.14 is >NR.sub.233 or >C.dbd.CR.sub.235 R.sub.236, R.sub.15 and R.sub.16, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (v) when R.sub.17 is >NR.sub.303 or >C.dbd.CR.sub.305 R.sub.306, R.sub.18 and R.sub.19, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (vi) when R.sub.20 is >NR.sub.313 or >C.dbd.CR.sub.315 R.sub.316, R.sub.21 and R.sub.22, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (vii) when R.sub.23 is >NR.sub.323 or >C.dbd.CR.sub.325 R.sub.326, R.sub.24 and R.sub.25, taken together, represent --C(O)NH-- or --C(O)NCH.sub.3 --; (ah) R.sub.29 and R.sub.30, taken together, optionally represent a group selected from the group consisting of hydrogen, hydroxy, and alkoxy, with the proviso that when R.sub.28 is >O or >S then R.sub.29 and R.sub.30, taken together, represent hydrogen; (ai) R.sub.1, R.sub.2 and R.sub.3, taken together, optionally represent a group selected from the group consisting of lower alkyl, arylalkyl, alkenyl, aryl, hydroxy, alkoxy, hydrogen, an N-terminal protecting group or peptide fragment of 1-8 residues similarly protected wherein each of the amino acids comprising the peptide fragment is independently selected from the 20 naturally occuring amino acids; (aj) R.sub.28, R.sub.29 and R.sub.30, taken together, optionally represent a group selected from an amino acid of dipeptide selected from from the 20 naturally occuring amino acids; (ak) R.sub.1, R.sub.2, R.sub.3 and R.sub.4, taken together, optionally represents a group selected from hydrogen, lower alkyl, arylalkyl, aryl, heterocyclic, or H.sub.2 NC(O)--, with the proviso that when R.sub.5 is >CH.sub.2 then R.sub.1, R.sub.2, and R.sub.3 and R.sub.4, taken together, may not be hydrogen; (al) R.sub.27, R.sub.28, R.sub.29 and R.sub.30, taken together, optionally represent a group selected from the group consisting of hydrogen, lower alkyl, aryl, and arylalkyl; (am) R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5, taken together, optionally represent an aryl or heterocyclic group; (an) R.sub.95, R.sub.96, R.sub.205, R.sub.206, R.sub.215, R.sub.216, R.sub.225, R.sub.226, R.sub.235, R.sub.236, R.sub.305, R.sub.306, R.sub.315, R.sub.316, R.sub.335 and R.sub.336 are independently selected from the group consisting of hydrogen, lower alkyl, aryl, arylalkyl, (cycloalkyl)alkyl, amidoalkyl, (carboxyamido)alkyl, ureidoalkyl, (heterocyclic)alkyl, and halosubstituted alkyl; (ao) R.sub.99, R.sub.202, R.sub.211, R.sub.221, R.sub.231, R.sub.302, R.sub.311, R.sub.321 and R.sub.331 are independently selected from the group consisting of hydrogen and lower alkyl; (ap) R.sub.100 is selected from the group consisting of hydrogen, lower alkyl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, (alkylamino)alkyl, hydroxyalkyl, guanidinoalkyl, carbosyalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, arylalkoxy, and sulfhydrylalkyl; (aq) R.sub.201 is selected from the group consisting of hydrogen, lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, (carboxyhydrazino)alkyl, ureidoalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)aklkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl; (ar) R.sub.203, R.sub.213, R.sub.223, R.sub.233, R.sub.303, and R.sub.313 are independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, (carboxyhydrazino)alkyl, ureidoalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, (thioarylalkoxy)alkyl, or protected sulfhydrylalkyl with the proviso that none of R.sub.203, R.sub.213, R.sub.223, R.sub.233, R.sub.303, or R.sub.313 may be a vinyl group or have a heteroatom directly attached to the nitrogen or separated from it by one methylene unit; (as) R.sub.210 is selected from the group consisting of hydrogen, lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, ureidoalkyl, (carboxyhydrazino)alkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl; (at) R.sub.220, R.sub.230, R.sub.301, R.sub.310, and R.sub.330 are independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, aminoalkyl, amidoalkyl, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyamido)alkyl, (carboxyhydrazino)alkyl, ureidoalkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, sulfhydrylalkyl, (aminothioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl; (au) R.sub.320 and R.sub.323 are selected from the group consisting of hydrogen, lower alkyl, alkenyl, aryl, benzyl, (cycloalkyl)alkyl, -(alkylene)-C(O)NR.sub.340 R.sub.341, -(alkylene)-NR.sub.342 R.sub.343, -(alkylene)-NR.sub.344 C(O)R.sub.345, hydroxyalkyl, guanidinoalkyl, carboxyalkyl, (carboxyhydrazino)alkyl, ureidoalkyl, heterocyclic substituted methyl, (thioalkoxy)alkyl, sulfhydraylalkyl, (aminothioalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl, where R.sub.340, R.sub.341, R.sub.342, and R.sub.343 are independently selected from hydrogen and lower alkyl; and R.sub.344 and R.sub.345 are independently selected from the group consisting of hydrogen, lower alkyl, and halosubstituted lower alkyl, with the proviso that R.sub.323 may not be a vinyl group or have a heteroatom directly attached to the nitrogen or separated from it by one methylene unit; (av) R.sub.325 and R.sub.325 are independently selected from the group consisting of hydrogen, lower alkyl, aryl, (cycloalkyl)alkyl, -(alkylene)-NR.sub.344 C(O)R.sub.345, (carboxyamido)alkyl, ureidoalkyl, (heterocyclic)alkyl, and halosubstituted alkyl, where R.sub.344 and R.sub.345 are as defined above; (aw) R.sub.201 and R.sub.202, R.sub.210 and R.sub.211, R.sub.220 and R.sub.221, R.sub.230 and R.sub.231, R.sub.301 and R.sub.302, R.sub.310 and R.sub.311, R.sub.320 and R.sub.321, and R.sub.330 and R.sub.331, each pair taken together, independently may optionally represent --(CH.sub.2).sub.z -- where z is an integer of from 2 to 6; all of the foregoing with the provisos that (i) when more than one sulfhydrylalkyl is present in the compound, the compound exists in the oxidized disulfide form producing a cyclic molecule, or the two sulfhydryl moieties are connected by a C.sub.2 to C.sub.8 alkylene chain and (ii) when the compound contains a free amino group and carboxyl group, they can be cyclized to give the corresponding lactam.
2. A compound as defined by claim 1 wherein R.sub.4, R.sub.7, R.sub.10, R.sub.13, R.sub.16, R.sub.19, R.sub.22, and R.sub.25 are independently selected fromthe group consisting of >NH and >N-(lower alkyl).
3. A compound as defined by claim 1 wherein R.sub.6, R.sub.9, R.sub.12, R.sub.15, R.sub.18, R.sub.21, R.sub.24, and R.sub.27 are independently selected from the group consisting of >C.dbd.O and >CH.sub.2.
4. A compound as defined by claim 1 wherein R.sub.5 is selected from the group consisting of >CR.sub.201 R.sub.202 ;>NR.sub.203 ; >C.dbd.CR.sub.205 R.sub.206, existing in the Z- or E-configuration; and substituted cyclopropyl of the formula ##STR48## where R.sub.201 is selected from the group consisting of lower alkyl, alkenyl, aryl, arylalkyl, (cycloalkyl)alkyl, amidoalkyl, (carboxyamido)alkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, and halosubstituted alkyl; R.sub.202 and R.sub.205 are selected from the group consisting of hydrogen and lower alkyl; R.sub.203 is selected from the group consisting of lower alkyl, alkenyl, arylalyl, (cycloalkyl)alkyl, amidoalkyl, (carboxyamido)alkyl, (heterocyclic)alkyl, (thioalkoxy)alkyl, (thioarylalkoxy)alkyl, protected sulfhydrylalkyl, with the proviso that R.sub.203 may not be a vinyl group or have a heteroatom directly attached to the nitrogen or separated from it by one methylene group; and R.sub.206 is selected fromt he group consisting of lower alkyl; aryl; arylalkyl; (cycloalkyl)alkyl; amidoalkyl; (carboxyamido)alkyl; (heterocyclic)alkyl; and halosubstituted alkyl.
5. A compound as defined in claim 1 wherein R.sub.8 is selected from the group consisting of >CR.sub.210 R.sub.211 ; >NR.sub.213 ; >C.dbd.CR.sub.215 R.sub.216, existing in either the Z- of E configuration; and substituted cyclopropyl of the formula ##STR49## where R.sub.210 is selected from the group consisting of arylalkyl; aminoalkyl; guanidinoalkyl; (heterocyclic)alkyl; (aminothioalkoxy)alkyl; R.sub.211 and R.sub.215 selected from hydrogen and lower alkyl; R.sub.213 is selected from the group consisting of arylalkyl; aminoalkyl; guanidinoalkyl; (heterocyclic)alkyl; and (aminothioalkoxy)alkyl; with the proviso that R.sub.213 may not have a herteroatom directly attached to the nitrogen or separated from it by one methylene unit; and R.sub.216 is selected from the group consisting of arylalkyl and (heterocyclic)alkyl.
6. A compound as defined by claim 1 wherein R.sub.26 is selected from the group consisting of >CR.sub.330 R.sub.331 ; >C.dbd.CR.sub.335 R.sub.356, existing in either the Z- or E-configuration; and substituted cyclopropyl of the formula ##STR50## where R.sub.330 is selected from the group consisting of arylalkyl, aminoalkyl, guanidinoalkyl, (heterocyclic)alkyl and (aminothioalkoxy)alkyl; R.sub.331 and R.sub.335 are independently selected from the group consisting of hydrogen and lower alkyl; and R.sub.336 is selected from the group consisting of arylalkyl and (heterocyclic)alkyl.
Non-Patent Literature (3)
- Kohl et al., vol. 20, Eur. J. Immunology, pp. 1463-1468, 1990.
- Hartung et al. vol. 130, No. 3, J. of Immunology, pp. 1345-1349, Mar. 1983.
- Hugli et al., Springer Seminars Immunopathology, 1984, pp. 193-219.